

Transcriptional profiling of human V δ 1 T cells reveals a pathogen-driven adaptive differentiation program

McMurray, Jack; von Borstel, Anouk; Taher, Taher; Syrimi, Eleni; Taylor, Graham; Sharif, Maria; Rossjohn, Jamie; Remmerswaal, Ester; Bemelman, Frederike; Vieira Braga, Felipe A; Chen, Xi; Teichmann, Sarah A; Mohammed, Fiyaz; Berry, Andrea; Lyke, Kirsten; Williamson, Kim; Stubbington, Michael; Davey, Martin; Willcox, Carrie; Willcox, Benjamin

DOI:

[10.1016/j.celrep.2022.110858](https://doi.org/10.1016/j.celrep.2022.110858)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

McMurray, J, von Borstel, A, Taher, T, Syrimi, E, Taylor, G, Sharif, M, Rossjohn, J, Remmerswaal, E, Bemelman, F, Vieira Braga, FA, Chen, X, Teichmann, SA, Mohammed, F, Berry, A, Lyke, K, Williamson, K, Stubbington, M, Davey, M, Willcox, C & Willcox, B 2022, 'Transcriptional profiling of human V δ 1 T cells reveals a pathogen-driven adaptive differentiation program', *Cell Reports*, vol. 39, no. 8, 110858. <https://doi.org/10.1016/j.celrep.2022.110858>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.


Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Transcriptional profiling of human $V\delta 1$ T cells reveals a pathogen-driven adaptive differentiation program

Graphical abstract



Authors

Jack L. McMurray, Anouk von Borstel, Taher E. Taher, ..., Martin S. Davey, Carrie R. Willcox, Benjamin E. Willcox

Correspondence

martin.davey@monash.edu (M.S.D.), c.r.willcox@bham.ac.uk (C.R.W.), b.willcox@bham.ac.uk (B.E.W.)

In brief

Using single-cell transcriptomics, TCR repertoire analysis, ATAC-seq, and immunophenotyping, McMurray et al. show naive $V\delta 1^+$ T cells can undergo transcriptional reprogramming to an effector state extremely similar to CD8 T_{EMRA} cells. Infections, including CMV and malaria, drive both clonotypic $V\delta 1^+$ T cell expansion and differentiation to this highly conserved effector program.

Highlights

- $V\delta 1^+$ T cells undergo transcriptional reprogramming from T_{naive} to $T_{effector}$ status
- $V\delta 1^+$ $T_{effector}$ cells are highly transcriptionally similar to CD8⁺ T_{EMRA} cells
- CD3 ligation of $V\delta 1^+$ T_{naive} cells induces $T_{effector}$ -linked transcription factors
- Infections drive transition from a $V\delta 1^+$ T_{naive} to $T_{effector}$ transcriptional profile



Article

Transcriptional profiling of human V δ 1 T cells reveals a pathogen-driven adaptive differentiation program

Jack L. McMurray,¹ Anouk von Borstel,² Taher E. Taher,¹ Eleni Syrimi,^{1,3} Graham S. Taylor,¹ Maria Sharif,¹ Jamie Rossjohn,^{2,4,5} Ester B.M. Remmerswaal,⁶ Frederike J. Bemelman,⁷ Felipe A. Vieira Braga,^{8,12} Xi Chen,^{8,13} Sarah A. Teichmann,^{8,9} Fiyaz Mohammed,¹ Andrea A. Berry,¹⁰ Kirsten E. Lyke,¹⁰ Kim C. Williamson,¹¹ Michael J.T. Stubbington,^{8,14} Martin S. Davey,^{1,2,15,*} Carrie R. Willcox,^{1,15,*} and Benjamin E. Willcox^{1,15,16,*}

¹Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK

²Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia

³Department of Haematology, Birmingham Children's Hospital, Birmingham B4 6NH, UK

⁴Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK

⁵Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, VIC 3800, Australia

⁶Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

⁷Renal Transplant Unit, Division of Internal Medicine, Academic Medical Centre, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

⁸Wellcome Sanger Institute, Cambridge, UK

⁹European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Cambridge CB10 1SD, UK

¹⁰Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA

¹¹Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

¹²Present address: Amsterdam UMC, Meibergdreef 9, 1105 Amsterdam, the Netherlands

¹³Present address: Department of Biology, Southern University of Science and Technology of China, Shenzhen, China

¹⁴Present address: 10x Genomics Inc., 6230 Stoneridge Mall Road, Pleasanton, CA 94588, USA

¹⁵These authors contributed equally

¹⁶Lead contact

*Correspondence: martin.davey@monash.edu (M.S.D.), c.r.willcox@bham.ac.uk (C.R.W.), b.willcox@bham.ac.uk (B.E.W.)
<https://doi.org/10.1016/j.celrep.2022.110858>

SUMMARY

$\gamma\delta$ T cells are generally considered innate-like lymphocytes, however, an “adaptive-like” $\gamma\delta$ compartment has now emerged. To understand transcriptional regulation of adaptive $\gamma\delta$ T cell immunobiology, we combined single-cell transcriptomics, T cell receptor (TCR)-clonotype assignment, ATAC-seq, and immunophenotyping. We show that adult V δ 1⁺ T cells segregate into TCF7⁺LEF1⁺Granzyme B^{neg} (T_{naive}) or T-bet⁺Eomes⁺BLIMP-1⁺Granzyme B⁺ (T_{effector}) transcriptional subtypes, with clonotypically expanded TCRs detected exclusively in T_{effector} cells. Transcriptional reprogramming mirrors changes within CD8⁺ $\alpha\beta$ T cells following antigen-specific maturation and involves chromatin remodeling, enhancing cytokine production and cytotoxicity. Consistent with this, *in vitro* TCR engagement induces comparable BLIMP-1, Eomes, and T-bet expression in naive V δ 1⁺ and CD8⁺ T cells. Finally, both human cytomegalovirus and *Plasmodium falciparum* infection *in vivo* drive adaptive V δ 1 T cell differentiation from T_{naive} to T_{effector} transcriptional status, alongside clonotypic expansion. Contrastingly, semi-invariant V γ 9⁺V δ 2⁺ T cells exhibit a distinct “innate-effector” transcriptional program established by early childhood. In summary, adaptive-like $\gamma\delta$ subsets undergo a pathogen-driven differentiation process analogous to conventional CD8⁺ T cells.

INTRODUCTION

$\gamma\delta$ T cells have been retained alongside $\alpha\beta$ T cells and B cells for ~450 million years, with each compartment expressing distinct but related somatically recombined antigen receptors (Hayday, 2000; Vantourout and Hayday, 2013). Functioning in both anti-microbial and anti-tumor immunity (Silva-Santos et al., 2019; Vantourout and Hayday, 2013), $\gamma\delta$ T cells display

a distinct tissue distribution, can be enriched at epithelial surfaces, and employ unique recognition modes to sense target cells dysregulated by infection or transformation (Willcox and Willcox, 2019; Willcox et al., 2020). This poorly understood process involves a combination of $\gamma\delta$ T cell receptor (TCR)-intrinsic but non-major histocompatibility complex (MHC)-restricted interactions, and TCR-extrinsic receptor/ligand interactions (Willcox and Willcox, 2019). The differentiation status of responding



$\gamma\delta$ T cells likely critically affects the outcome of such recognition processes.

How established lymphocyte differentiation paradigms apply to human $\gamma\delta$ T cell function is unclear. While $\gamma\delta$ T cells are often assumed to be “innate-like,” or “bridging innate and adaptive immunity,” increasing evidence suggests that parallel innate-like and adaptive paradigms operate in the human $\gamma\delta$ T cell compartment, and apply to discrete $\gamma\delta$ T cell subsets. $V\gamma 9^+V\delta 2^+$ T cells prevalent in adult peripheral blood (PB) seem to adopt an innate-like immunobiology (Davey et al., 2018b; Willcox et al., 2018). They display a semi-invariant TCR repertoire from birth (Davey et al., 2018b), respond polyclonally to host and microbially derived phosphoantigens (Davey et al., 2018b), and display polyclonal recognition of butyrophilin superfamily (BTN)-2A1 via germline-encoded regions of the $V\gamma 9^+$ TCR chain (Karunakaran et al., 2020; Rigau et al., 2020). Similarly, human intestinal $\gamma\delta$ T cells include an intraepithelial lymphocyte (IEL) population polyclonally reactive to butyrophilin-like 3.8 heterodimer via germline-encoded regions of the $V\gamma 4^+$ TCR chain (Melandri et al., 2018; Willcox et al., 2019), likely reflecting a distinct innate-like biology.

In contrast, PB $V\delta 1^+$ T cells adopt a more adaptive-like immunobiology (Davey et al., 2017; Ravens et al., 2017), as they display highly focused clonal expansion, including after viral (Farnault et al., 2013; Fujishima et al., 2007; Ravens et al., 2017) or parasitic (Rutishauser et al., 2020; von Borstel et al., 2021) infection, concomitant with apparent differentiation of select clones from a TCR-diverse T_{naive} pool to generate long-lived, TCR-focused $T_{effector}$ populations (Davey et al., 2018a; Davey et al., 2017; von Borstel et al., 2021). Also, $V\delta 1^+$ T_{naive} and $T_{effector}$ subsets bear immunophenotypic similarities to conventional adaptive $CD8^+$ T_{naive} and T_{EMRA} populations, respectively (Davey et al., 2018a). Recently we defined a subset of $V\gamma 9^{neg}V\delta 2^+$ T cells that shares critical adaptive-like hallmarks with PB $V\delta 1^+$ T cells (Davey et al., 2018b) and is linked to antiviral (Davey et al., 2018b; Kaminski et al., 2020) and autoimmune (Bank et al., 1995; Hohlfeld et al., 1991; Pluschke et al., 1992) responses. The relevance of these observations likely extends to solid tissues. Hepatic $\gamma\delta$ T cells included heavily expanded $V\delta 1^+$ and $V\gamma 9^{neg}V\delta 2^+$ $T_{effector}$ clonotypes, with some $V\delta 1^+$ clonotypes shared with PB, and $V\delta 1^+$ $T_{effector}$ prevalence linked to viral exposure (Davey et al., 2018b; Hunter et al., 2018). Moreover, adaptive-like $V\gamma 4^{neg}V\delta 1^+$ T cells were recently shown to outcompete endogenous $\gamma\delta$ T cell populations during intestinal autoimmunity (Mayassi et al., 2019). In summary, a seemingly adaptive-like $\gamma\delta$ immunobiology appears to drive potent T cell responses in several contexts, including viral and parasitic infections, and in autoimmunity.

While conventional $\alpha\beta$ T cell differentiation is relatively well understood, the transcriptional basis of adaptive-like $\gamma\delta$ T cell differentiation has not been addressed. $CD8^+$ T cells transition from a TCR-diverse naive status through a series of differentiation states, via altered expression of a set of critical transcription factors (Fu et al., 2017; Henning et al., 2018; Kaech and Cui, 2012; Lazarevic et al., 2013; Vieira Braga et al., 2015). Initial antigen recognition and TCR signaling, culminating in clonal expansion, is considered critical in initiating this adaptive transition. Whether this model applies to adaptive-like $\gamma\delta$ T cell populations

is unclear. To date, transcriptional analyses of $\gamma\delta$ T cells have stressed features of “innateness” shared between innate-like $\gamma\delta$ subsets and unconventional $\alpha\beta$ T cells, notably mucosal-associated innate T cells (MAITs) and invariant natural killer T cells (iNKTs) (Gutierrez-Arcelus et al., 2019; Koay et al., 2019; Pizzolato et al., 2019), but have not delineated differentiation processes fundamental to “adaptive-like” $\gamma\delta$ T cell responses. To address this, we analyzed the transcriptional paradigms underpinning human $\gamma\delta$ T cell function in both adaptive-like ($V\delta 1^+$, $V\gamma 9^{neg}V\delta 2^+$) and innate-like ($V\gamma 9^+V\delta 2^+$) subsets. We reveal striking similarities in transcriptional regulatory mechanisms between adaptive-like $\gamma\delta$ T cell and $CD8^+$ $\alpha\beta$ T cell populations, including a tight link between clonotypic expansion and differentiation, and suggest they adopt a fundamentally different transcriptional control paradigm to innate-like $V\gamma 9^+V\delta 2^+$ T cells.


RESULTS

Human PB $V\delta 1^+$ T cells exhibit two transcriptional profiles

To understand adaptive-like $\gamma\delta$ T cell differentiation, we performed single-cell transcriptomic analyses of human $V\delta 1^+$ T cells. $V\delta 1^+$ T cells include distinct phenotypically naive ($CD27^{hi}$) and effector-like ($CD27^{lo/neg}$) sub-compartments (Davey et al., 2017, 2018a). A total of 447 single $V\delta 1^+$ T cells were sorted from 3 individuals with cell surface staining for $CD27$ and $CD45RA$; roughly equal numbers of $CD27^{hi}$ and $CD27^{lo/neg}$ cells were sorted (Figures S1A and S1B), with acceptable quality control statistics (transcripts per cell, genes per cell, fraction of mitochondrial reads per cell) (Figure S1C). Principal-component dimension reduction analysis and subsequent unsupervised clustering of $V\delta 1^+$ T cell transcriptomes identified two clusters of cells (Figures 1A–1C).

Differential gene expression comparisons between cluster 1 and cluster 2 $V\delta 1^+$ T cells revealed 368 differentially expressed genes (Table S1). Cluster 1 $V\delta 1^+$ T cells exhibited enhanced expression of *SELL*, *IL7R*, and *CCR7* and low expression of effector-related genes, including *CX3CR1*, *GZMA*, and *PRF1* (Figures 1D–1F), whereas cluster 2 $V\delta 1^+$ T cells had an inverse expression pattern. This indicated close concordance with cell surface $V\delta 1^+$ T_{naive} and $T_{effector}$ (cluster 1 and cluster 2, respectively) phenotypes we previously defined and noted were similar to $CD8^+$ T_{naive} and T_{EMRA} cells, respectively (Davey et al., 2017, 2018a). Indexing of individual transcriptomes indicated a 91.1% concordance with flow phenotype (Figure S1D), whereby cluster 1 $V\delta 1^+$ T cells were predominantly $CD27^{hi}$ and cluster 2 $V\delta 1^+$ T cells $CD27^{lo}$, confirming $V\delta 1^+$ T_{naive} and $T_{effector}$ status, respectively (Figures S1E–S1H). While cluster 1 and 2 $V\delta 1^+$ T cell transcriptomes (referred to as $V\delta 1^+$ T_{naive} and $T_{effector}$ programs) differentially expressed several key transcription factors, including *TCF7*, *LEF1*, and *TBX21* (Figure 1F), the challenges of detecting low expression genes using single-cell transcriptomics suggested that this was an incomplete list.

We next probed the link between $V\delta 1^+$ clonotypic expansion and possession of a $T_{naive}/T_{effector}$ program. We extended the TraCeR algorithm (Stubbington et al., 2016) to reconstruct human γ and δ TCR sequences from standard single-cell transcriptomes. This leveraged approaches previously applied to $\alpha\beta$ TCR



(legend on next page)

sequence extraction (Stubbington et al., 2016), although the γ and δ complementarity determining region 3 length parameters were informed by bulk TCR sequencing on human $\gamma\delta$ T cells (Davey et al., 2017, 2018b; Hunter et al., 2018). We reconstructed both γ and δ TCR sequences from $\sim 70\%$ of cells, a similar success rate to $\alpha\beta$ T cells (Stubbington et al., 2016). Whereas $\gamma\delta$ TCR clonotypes assigned to the T_{naive} cellular cluster were overwhelmingly distinct “singlets” (95.6%), expanded clonotypes (those observed in more than one cell) were restricted almost entirely (95.3%) to $V\delta 1^+$ cells bearing a $T_{effector}$ transcriptional program (cluster 2) (Figure 1G). Compelling statistical significance ($p < 2.2e-16$, Pearson’s chi-square test, Yates continuity correction) was evident in three associations: cluster status (1 or 2) with sorted phenotype ($CD27^{hi}$ or $CD27^{lo/neg}$); clonality status (singlet or expanded clonotype) with cluster status (1 or 2); between clonality status (singlet or expanded clonotype) and sort phenotype ($CD27^{hi}$ or $CD27^{lo/neg}$) (Figures S1E–S1H). Finally, TCR sequence analysis enabled us to probe transcriptional differences between distinct expanded clonotypes. While few interclonal differences were observed, two observations validated the approach. Firstly, interclonal discrepancies in $V\gamma$ chain expression were apparent and, secondly, expression of *XIST*, an X-linked transcript involved in X chromosome inactivation in females, was restricted to the female donor’s major clone (Figures S1I and S1J; Table S2).

These results suggested that distinct naive and effector transcriptional programs underpin $V\delta 1^+$ T cell differentiation, that these two states can be accurately delineated by CD27 status, and established that effector status was intrinsically linked to clonotypic expansion at a single-cell level.

Analogous transcriptional reprogramming in $CD8^+$ and $V\delta 1^+$ T cells

To gain a deeper knowledge of the $V\delta 1^+$ T_{naive} and $T_{effector}$ transcriptional programs and how they compare with $CD8^+$ differentiation states with a similar cell surface phenotype, we performed bulk RNA-seq on $V\delta 1^+$ T_{naive} ($CD27^{hi}$) and $T_{effector}$ ($CD27^{lo}$) populations and both $CD8^+$ T_{naive} and T_{EMRA} populations, sorted from human PB mononuclear cells from healthy donors or buffy packs (see STAR Methods). Using all filtered genes, multidimensional scaling revealed strong similarity between $CD8^+$ T_{EMRA} and $V\delta 1^+$ $T_{effector}$ populations (Figure 2A), both of which were clearly separated from $CD8^+$ T_{naive} and $V\delta 1^+$ T_{naive} populations

in dimension 1. While $V\delta 1^+$ T_{naive} and $CD8^+$ T_{naive} cells were broadly similar transcriptionally, they exhibited some differences, particularly in dimension 2; however, this made a minor contribution to the observed variance (7%). In contrast, $V\delta 1^+$ T_{naive} and $CD8^+$ T_{naive} cells were more concordant in dimension 1, which made a larger contribution (37%).

These data are in accordance with, but extend, our previous phenotypic data on adaptive-like $V\delta 1^+$ T cells (Davey et al., 2017, 2018a). Differential gene expression analysis between $V\delta 1^+$ $T_{naive}/T_{effector}$ populations revealed 1,337 differentially expressed transcripts (Figure 2B), substantially more than revealed by single-cell analysis.

We next compared genes differentially expressed in both $V\delta 1^+$ and $CD8^+$ subpopulations. Interestingly, 86% of all genes differentially expressed between $V\delta 1^+$ $T_{naive}/T_{effector}$ populations were also differentially expressed between $CD8^+$ T_{naive}/T_{EMRA} (Figure 2C). Within this conserved set of 1,150 differentially expressed genes were those canonically related with effector (*GNLY*, *GZMA/B/H*, and *PRF1*) and naive (*CCR7*, *LEF1*) status (Figure 2B). Genes downregulated in $V\delta 1^+$ $T_{effector}$ cells contributed more strongly than upregulated genes to this core gene list (Figure S2A). Heatmap analysis, using hierarchical clustering, on this 1,150-gene list segregated $V\delta 1^+$ $T_{effector}$ cells with $CD8^+$ T_{EMRA} cells, and the $V\delta 1^+$ T_{naive} subset alongside $CD8^+$ T_{naive} cells, highlighting clear concordance of gene expression within each subgroup (Figure 2D). Interestingly, $V\delta 1^+$ $T_{effector}$ populations were not clustered together as a group, but instead clustered among $CD8^+$ T_{EMRA} populations, emphasizing close transcriptional concordance (Figure 2D). In contrast, T_{naive} subsets clustered separately by compartment ($V\delta 1^+$ and $CD8^+$ T cells) (Figure 2D), consistent with greater transcriptional differences between naive $V\delta 1^+$ and $CD8^+$ T cells (Figure 2A).

Gene set enrichment analysis highlighted 11 pathways significantly upregulated in $V\delta 1^+$ $T_{effector}$ versus $V\delta 1^+$ T_{naive} subsets (Figures 2E; Table S3). Chief among these were effector/cytotoxicity, antigen processing/presentation, and IFN- γ -responsive genes, mirroring changes in $CD8^+$ T_{EMRA} versus T_{naive} compartments (Figures S2B; Table S3). Also, analysis of bespoke gene sets linked to cytotoxic molecules (Figure S3A), cytokine and chemokine receptors (Figure S3B), adhesion molecules (Figure S3C), and TCR/co-stimulatory molecules (Figure S3D) underlined close concordance between $V\delta 1^+$ $T_{effector}$ and

Figure 1. Clustering of single-cell transcriptomes reveals two distinct states of $V\delta 1^+$ cells reminiscent of effector and naive phenotypes
(A and B) Principal-component analysis was performed on single-cell RNA sequencing data from 447 FACS-sorted $V\delta 1^+$ cells ($CD27^{hi}$ versus $CD27^{lo/neg}$) from three donors. (A) An elbow plot was constructed using the 20 dimensions. An “elbow” is observed at PC2. (B) A JackStraw plot was used to investigate the top 5 principal components (PCs). PC1 and PC2 were significant and used for visualization.
(C) Shared nearest neighbor clustering was used to find clusters in the data. Two clusters were found and colored.
(D) A heatmap was created using the top 30 genes contributing to the differences between cluster 1 and 2 (PC1). An even number of positive and negative factors are shown. These highlight genes previously shown to be associated with effector or naive status.
(E) Expression of genes previously shown to be associated with either effector (top) or naive (bottom) status were projected onto the PCA plot. Purple indicates higher expression.
(F) Differential gene expression between cluster 1 (blue) and cluster 2 (red) cells revealed 368 differentially expressed genes. Only those that had a LogFC greater than 0.25 and an adjusted p value of less than 0.05 were colored (Bonferroni corrected). Notable genes previously associated with effector or naive status are labeled.
(G) TCR clonality analysis. Thirteen expanded clonotypes were identified by the analysis (clones A–M), and projected onto the PCA taken from (B). “X” represents cells with a unique TCR sequence. Cells bearing expanded clonotypes fall within $CD27^{lo/neg}$ sorted cells and almost exclusively within the “ $T_{effector}$ ” cluster (cluster 2).




Figure 2. Bulk RNA sequencing on sorted Vδ1 populations reveals transcriptomic similarity between Vδ1+ and CD8+ populations

(A) Multidimensional scaling plot using 12,627 filtered genes revealed close transcriptomic similarity between bulk sorted Vδ1⁺ T_{effector} and CD8⁺ T_{EMRA}. (B) Differential gene expression between Vδ1⁺ T_{effector} (red) and Vδ1⁺ T_{naive} (blue) revealed 1,337 differentially expressed transcripts. Among these were genes related to effector or naive status. (C) Differential gene expression between Vδ1⁺ and CD8⁺ populations revealed a core of 1,150 differentially expressed transcripts shared between comparisons. (D) Hierarchically clustered heatmap of the core 1,150 transcripts differentially expressed in both Vδ1⁺ and CD8⁺ comparisons highlighted similarity between Vδ1⁺ T_{effector} and CD8⁺ T_{EMRA} cells and between Vδ1⁺ T_{naive} and CD8⁺ T_{naive} cells. Colors for the cell populations are taken from (A). Genes are plotted row-wise and scaled to represent Z scores across samples. (E) Gene set enrichment analysis using the GO and KEGG databases revealed enrichment of 11 pathways associated with effector function in Vδ1⁺ T_{effector} cells. In contrast, 6 pathways were associated with Vδ1⁺ T_{naive} status. Genes differentially expressed between Vδ1⁺ populations were used as input. Cytoscape was used to produce the enrichment map, where node size indicates the gene set size, edge thickness represents Jaccard similarity scores between gene sets, and node color is based on FDR value. Only gene sets with an FDR below 0.05 are shown.

CD8⁺ T_{EMRA} cells. Conversely, a minority of processes were up-regulated on Vδ1⁺ T_{naive} cells relative to Vδ1⁺ T_{effector} cells, including protein translation and metabolism (Figure 2E); these were also upregulated on CD8⁺ T_{naive} cells versus CD8⁺ T_{EMRA} cells (Figure S2B). Of note, several activating co-stimulatory molecules (e.g., *CD28*, *CD27*, and *JAML*) displayed higher expression on both Vδ1⁺ T_{naive} and CD8⁺ T_{naive} cells relative to Vδ1⁺ T_{effector} and CD8⁺ T_{EMRA} subsets, whereas several inhibitory co-signaling molecules (e.g., *PDCD1*, *TIGIT*, and *LAG3*) were increased on T_{effector/EMRA} cells (Figure S3D). Furthermore, numerous NKR, including *KLRK1* (NKG2D), *NCR1* (NKp46), and *KLRF1* (NKp80), were upregulated in Vδ1⁺ T_{effector} and CD8⁺ T_{EMRA} cells relative to T_{naive} subsets (Figure S3E). Vδ1⁺ and CD8⁺ T_{effector} subset concordance was close, with differential gene expression analysis revealing just 20 transcripts (Table S1). Of these, seven were TCR chain-specific genes, and two, *CD8A* and *CD8B*, known to be expressed differentially in CD8⁺ αβ versus γδ T cells, leaving 11 genes. Several of these (*CD5*, *THEMIS*, and *SIT1*) have established roles regulating TCR signaling thresholds in response to peptide MHC (Fu et al., 2009; Simeoni et al., 2005; Voisinne et al., 2018), and were preferentially expressed in CD8⁺ T cells. *ITGAD* was upregulated in Vδ1⁺ T_{effector} cells, consistent with previous findings (Siegers et al., 2017). Notably, the Vδ1⁺ T_{naive} compartment displayed marginally higher transcription of several NKR genes than CD8⁺ T_{naive} cells, with some specific NKRs (NKG2A/C/E (*KLRC1/3*), and *FCRL3*) displaying particularly high relative expression in the Vδ1⁺ T_{naive} compartment (Figure S3E).

A shared set of TCR-linked transcription factors underpin Vδ1⁺ and CD8⁺ T cell differentiation

Transcriptional analyses also indicated differential expression of a core set of transcription factors delineated CD8⁺/Vδ1⁺ T_{naive} versus CD8⁺ T_{EMRA}/Vδ1⁺ T_{effector} subsets. *TCF7*, *LEF1*, and *Myc* were enriched in T_{naive} subsets, whereas *TBX21* (T-bet), and *PRDM1* (BLIMP-1) were enriched in Vδ1⁺ T_{effector} cells and CD8⁺ T_{EMRA} cells (Figures 1E and 2B). Overall, 122 transcription factors were significantly differentially expressed between Vδ1⁺ T_{naive} and T_{effector} subsets (Table S4). Moreover, hierarchical clustering based on these transcription factors separated Vδ1⁺ T_{naive} with CD8⁺ T_{naive} cells as distinct clusters, whereas Vδ1⁺ T_{effector} cell clustering was interspersed with that of CD8⁺ T_{EMRA} cell populations (Figure S3F). Flow cytometry confirmed differential transcription factor expression at a protein level, establishing equivalently high TCF7 and IL-7Rα expression in Vδ1⁺ and CD8⁺ T_{naive} cells and absence in T_{effector} cells, whereas T-bet, Eomes, and BLIMP-1 were strikingly and equivalently upregulated in Vδ1⁺ T_{effector} and CD8⁺ T_{EMRA} cells relative to T_{naive} subsets (Figures 3A and 3B). Also, HOBIT expression was higher in Vδ1⁺ T_{effector} and CD8⁺ T_{EMRA} cells than T_{naive} cells (Figures 3A and 3B). T-bet and Eomes expression correlated with lower CD27 expression (Figures 3C and 3D). These changes correlated with established differentiation markers, as confirmed by assessment of IL7Rα (T_{naive}) and CXCR3 (Davey et al., 2017) (T_{effector}/T_{EMRA}) expression (Figures 3A and 3B). Of note, despite transcriptional differences in CXCR3 between Vδ1⁺ T_{naive} and CD8⁺ T_{naive} subsets, both expressed CXCR3 protein, whereas

CXCR3 expression was lower on Vδ1⁺ T_{effector} and CD8⁺ T_{EMRA} cells (Figures S4A–S4C).

To address how Vδ1⁺ T_{naive} to T_{effector} transition affected chromatin structure, we carried out assay for transposase-accessible chromatin using sequencing (ATAC-seq) on purified Vδ1⁺ and CD8⁺ subpopulations (Figure S4D; Table S5). For a defined subset of loci, clear and analogous differences in chromatin accessibility were observed between CD8⁺/Vδ1⁺ T_{naive} populations and CD8⁺ T_{EMRA}/Vδ1⁺ T_{effector} subsets (Figure S4D). These included *CD27*, which was more active in T_{naive} Vδ1⁺/CD8⁺ T cells than in T_{EMRA}/Vδ1⁺ T_{effector} subsets. Conversely, *PRDM1* (BLIMP-1) and *EOMES* and *CX3CR1* all showed an inverse pattern of accessibility. In contrast, numerous loci displayed unaltered chromatin accessibility between CD8⁺/Vδ1⁺ T_{naive} populations and CD8⁺ T_{EMRA}/Vδ1⁺ T_{effector} subsets, including *CD3E*, *B2M*, and *RPL13A* (Figure S4E). These results confirm that Vδ1⁺ T_{naive} and T_{effector} subsets represent two distinct differentiation states.

In CD8⁺ T cells, downregulation of TCF7/LEF1 and upregulation of Eomes, T-bet, and BLIMP-1 are associated with exposure of T_{naive} subsets to antigen-induced TCR signaling (Fu et al., 2017; Kaech and Cui, 2012; Lazarevic et al., 2013; Willinger et al., 2006). Consistent with this also operating in Vδ1⁺ T cells, Vδ1⁺ clonal expansion correlates with a transition from T_{naive} to T_{effector} status. To assess whether TCR signaling also induced similar changes in adaptive γδ T cells, we stimulated purified Vδ1⁺ T cells with plate-bound CD3 antibodies and assessed changes in transcription factor expression and phenotype in the Vδ1⁺ CD27^{hi} (i.e., T_{naive}) subset (Figure 3E). Exposure of Vδ1⁺ T cells to CD3 stimulation induced BLIMP-1, Eomes, and T-bet expression in CD27^{hi} Vδ1⁺ T cells. TCR-induced expression of BLIMP-1 was previously shown for CD4⁺ T cells (Martins et al., 2006); however, here we show this extends to Vδ1⁺ and also CD8⁺ T cells (Figure 3F). While IL-2 (Figures 3E and 3F) and anti-CD28 (Figures S4F and S4G) appeared to amplify transcription factor expression, TCR signaling induced by anti-CD3 had the most profound effect on BLIMP-1, Eomes, and T-bet upregulation. This suggested that TCR signaling in Vδ1⁺ T_{naive} cells can initiate transition from T_{naive} to T_{effector} status, mirroring CD8⁺ T cell differentiation.

The Vδ1⁺ T_{effector} program permits rapid cytokine production kinetics

Production of inflammatory cytokines and enhanced cytotoxicity are hallmarks of γδ T cell responses. While cytotoxic pathways were upregulated at both the transcriptional and protein level in resting Vδ1⁺ T_{effector} cells, cytokines were not differentially transcribed in Vδ1⁺ T_{effector} relative to T_{naive} cells. Yet, ATAC-seq indicated substantially greater chromatin accessibility at the *IFNγ* locus in CD8⁺ T_{EMRA} than CD8⁺ T_{naive} cells. A similar pattern was observed in Vδ1⁺ subsets, albeit with a lower fold difference due to greater accessibility in Vδ1⁺ T_{naive} than CD8⁺ T_{naive} cells. This indicated the potential for enhanced/expedited IFN-γ production in T_{effector}/T_{EMRA} subsets (Figure S4H). While similarly low ATAC-seq reads mapped to the TNF-α locus in T_{naive} and T_{effector}/T_{EMRA} subsets, our analyses were performed on resting cells, and further signals may be needed to affect chromatin accessibility at this locus. Also, differential transcription factor expression in the T_{naive} versus T_{effector}/T_{EMRA} states




Figure 3. Transcription factors key to CD8⁺ differentiation demonstrate analogous and TCR-dependent expression in Vδ1⁺ subsets

(A) Flow cytometry staining of transcription factors and homing receptors key to effector/naive status highlight similarities between Vδ1⁺ T_{effector} and CD8⁺ T_{EMRA} and Vδ1⁺ T_{naive} and CD8⁺ T_{naive} populations. Representative of four donors.

(B) Percentage of each naive and effector marker in each total cell population (CD8⁺ T_{naive}, CD8⁺ T_{EMRA}, Vδ1⁺ T_{naive}, Vδ1⁺ T_{effector}). Graphs show mean ± SEM from four donors.

(C and D) Overlaid flow cytometry dot plots of the transcription factors Eomes and T-bet in total Vδ1⁺ and CD8⁺ populations (C) and the overlap of each transcription factor with CD27 (D). Representative of four donors. Data were analyzed by one-way ANOVA with Tukey's multiple comparisons (****p < 0.0001).

(E and F) TCR stimulation of enriched T_{naive} cells leads to expression of T_{effector} transcription factors. Flow cytometric analysis of BLIMP-1, Eomes, T-bet, and HOBIT in Vδ1⁺ T_{naive} (E) and CD8⁺ T_{naive} (F) on day 0 (unstimulated) and day 6 of stimulation with either plate-bound anti-CD3 antibodies or IL-2. The top panel shows representative histograms for flow cytometric analysis, whereas the lower panel shows bar charts representing data from four donors. Data were analyzed by one-way ANOVA with Tukey's multiple comparisons (*p < 0.05, **p < 0.01). Only significant comparisons are shown.

may influence cytokine production, as suggested for TCF7-mediated repression of IFN-γ expression in CD4 T cells (Maier et al., 2011). To test if their distinct chromatin and transcriptional profiles affected cytokine production, we stimulated both Vδ1⁺ T_{naive} and T_{effector} subsets and assessed production of IL-2, IL-

17A, GM-CSF, IFN-γ, TNF-α, and CCL5. Vδ1⁺ T_{effector} cells displayed dramatically amplified and expedited production of IFN-γ, TNF-α, and CCL5 relative to Vδ1⁺ T_{naive} cells (but not IL-2, IL-17A, or GM-CSF) (Figures 4A, 4B, and S4I) in a manner highly analogous to CD8⁺ T_{EMRA} versus T_{naive} subsets. This




Figure 4. V δ 1⁺ T_{effector} and CD8⁺ T_{EMRA} populations display similar cytokine production profiles

(A) Cytokine production by V δ 1⁺ T_{effector} and CD8⁺ T_{EMRA} and T_{naive} populations after 4 h of PMA/ionomycin stimulation. Overlaid contour flow cytometry plots of gated populations of V δ 1⁺ (top) and CD8⁺ (bottom).

(B) Graphs highlight mean \pm SEM and represent three donors. Data were analyzed by two-way ANOVA with Sidak's multiple comparisons (* $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$). Only significant comparisons are shown.

NKRs (*KLRK1* [NKG2A]), co-stimulatory molecules (*JAML*), cytokine receptors (*IL23R*), sphingolipid metabolism genes (*SPTSSB* and *KDSR*), and an alternative splicing gene (*HNRNPLL*), which is responsible for generation of the CD45RO isoform (Oberdoerffer et al., 2008) expressed by V δ 2⁺ T cells (Parker et al., 1990), but not generally by V δ 1⁺ T_{effector} or CD8⁺ T_{EMRA} cells. V γ 9⁺V δ 2⁺ T cells also had a distinct overall profile of chemokine/cytokine receptors (Figure S5C) and transcription factors (Figure S5D) compared with V δ 1⁺ T_{effector}/CD8⁺ T_{EMRA} subsets. While they shared expression of *TBX21*, *EOMES*, *ZEB2*, and *PRDM1* with these effectors, like T_{naive} subsets they were enriched for *Myc*, and also for both *ZBTB16* (PLZF, also expressed in iNKT and MAIT cells)

suggests that V δ 1⁺ T_{naive} to T_{effector} transition, as for CD8⁺ T cells, results in transcriptional reprogramming and chromatin remodeling, enabling increased cytotoxicity and cytokine production, allowing amplified and expedited effector responses upon subsequent stimulation.

V γ 9⁺V δ 2⁺ T cells display a distinct innate-like effector transcriptome from early life

RNA-seq data from V γ 9⁺V δ 2⁺ T cells sorted from healthy adults indicated an effector rather than naive transcriptional program. Multidimensional scaling (Figure 5A) positioned V γ 9⁺V δ 2⁺ cells closer to V δ 1⁺/CD8⁺ T_{effector} than T_{naive} populations. Unsupervised hierarchical clustering based on the 1,150 genes differentially expressed between T_{naive} and T_{effector} subsets also clustered V γ 9⁺V δ 2⁺ cells with effector V δ 1⁺/CD8⁺ subsets (Figures 5B and S5A). Similar clustering approaches highlighted V γ 9⁺V δ 2⁺ T cell alignment with V δ 1⁺ T_{effector}/CD8⁺ T_{EMRA} populations based on bespoke lists of cytotoxicity markers and NK receptors (Figures 5C and S5B). Moreover, V γ 9⁺V δ 2⁺ T cells were at least as potent producers of IFN- γ , TNF- α , and CCL5 upon anti-CD3 stimulation as V δ 1⁺ T_{effector} cells (Figures 4B and 5D).

Despite such similarities, several genes were enriched in V γ 9⁺V δ 2⁺ relative to V δ 1⁺ T_{effector} cells (Figure 5E; Table S1), including transcription factors (*CEBP δ* , *SATB1*, and *ROR γ T*),

and *CEBPD* (C/EBP δ), which is also expressed by MAIT cells and supports CCR6 expression (Lee et al., 2018) on V γ 9⁺V δ 2⁺ T cells (Figure S5C). Higher transcription of ROR γ T and IL-23R in V γ 9⁺V δ 2⁺ than in V δ 1⁺ T_{effector} cells is consistent with the suggestion that adult V γ 9⁺V δ 2⁺ T cells may retain some IL-17-producing cells (Tan et al., 2020). Also, flow cytometry confirmed that, in adults, a high frequency of V γ 9⁺V δ 2⁺ T cells expressed PLZF, NKG2A, and CXCR3 (Figure 5F). Therefore, in adults, almost all V γ 9⁺V δ 2⁺ T cells adopt an “innate-like effector” program distinct from adaptive subsets.

To assess if V γ 9⁺V δ 2⁺ T cells were effector-like from birth, we analyzed cord blood samples, a setting where V δ 1⁺ T cells subsets are phenotypically highly naive and have an unfocused TCR repertoire. Cord blood V γ 9⁺V δ 2⁺ T cells displayed high levels of Eomes, HOBIT, CD161, and IL-7R α . However, relative to adult V γ 9⁺V δ 2⁺ T cells, they had lower T-bet, HOBIT, granzyme A, and perforin expression, indicating an immature effector phenotype (Figures 5G and 5H). However, V γ 9⁺V δ 2⁺ T cells in young healthy children (≤ 3 years) displayed a transition to a T-bet⁺ HOBIT⁺ phenotype, increased levels of granzyme A and perforin, and a dominant CD45RO⁺ phenotype (Figures 5G and 5H). These results suggest V γ 9⁺V δ 2⁺ T cells are a dedicated effector subset at birth but transition to a more mature innate-effector program similar to that present in adults, in early life.




Figure 5. Transcriptomic analysis of V δ 2⁺ cells reveals an effector-like program

(A) Multidimensional scaling plot on 12,627 filtered genes placed V γ 9⁺V δ 2⁺ T cells closer to V δ 1⁺ T_{effector} and CD8⁺ T_{EMRA} than to T_{naive} cells, highlighting increased transcriptional similarity of V γ 9⁺V δ 2⁺ to effector populations.

(legend continued on next page)

Adaptive $\gamma\delta$ T cell subsets undergo transcriptional reprogramming *in vivo*

To assess transition from T_{naive} to $T_{effector}$ status in adaptive-like $\gamma\delta$ T cells *in vivo*, we examined the transcriptional phenotype of such cells before and after pathogen challenge in two separate human *in vivo* infection models; firstly CMV infection in patients undergoing kidney transplantation, and secondly repeated controlled human malaria challenge (CHMI) in malaria-naive individuals. Changes in $V\delta 1^+$ T cells in patients who became CMV seropositive after transplantation were consistent with an infection-induced increase in the proportion of $CD27^{lo/neg}$ T-bet⁺ Eomes⁺ granzyme B⁺ $T_{effector}$ cells (Figure 6A). We also examined changes in the adaptive-like $V\gamma 9^{neg}V\delta 2^+$ T cell compartment. This was previously shown to undergo clonotypic expansion with concomitant phenotypic differentiation from a naive TCR-undefocused $CD27^{hi}$ repertoire to a $CD27^{lo/neg}$ phenotype after CMV infection (Davey et al., 2018b; Kaminski et al., 2020). Here, we demonstrate that while CMV-seronegative donor $V\gamma 9^{neg}V\delta 2^+$ T cells lacked T-bet, HOBIT and BLIMP-1, these markers were markedly upregulated upon CMV infection and seroconversion post-transplantation, alongside transition from $CD27^{hi}$ to $CD27^{lo/neg}$ status, suggesting transition to the $T_{effector}$ transcriptional program (Figure 6B); in contrast, $V\gamma 9^+V\delta 2^+$ T cells were strongly granzyme A/B⁺, T-bet⁺ and Eomes⁺ before and after CMV infection and seroconversion (Figure S6A). Secondly, CHMI with *Plasmodium falciparum* drives clonal expansion of $V\delta 1^+$ T cells (Rutishauser et al., 2020; von Borstel et al., 2021), providing an opportunity to assess acquisition of transcription factors in this context. At baseline, in a malaria-naive individual, 76%–78% of $V\delta 1^+$ T cells expressed a $CD27^+$ T_{naive} phenotype (Figure 6C). Upon sequential CHMIs over 378 days, $V\delta 1^+$ T cells transitioned from a T_{naive} to $T_{effector}$ subtype, as indicated by loss of CD27 and acquisition of T-bet, HOBIT, and Eomes—mirroring that seen after CMV seroconversion; HOBIT expression was most pronounced after a fourth infectious challenge (Figure 6C). Finally, in healthy children (12 months to 14 years) $V\delta 1^+$ $T_{effector}$ cell levels correlated with the percentage of $CD8^+$ $T_{effector}$ cells ($T_{CM} + T_{EM} + T_{EMRA}$) as measured by cell surface phenotype ($CD27^{lo/neg}$ $V\delta 1^+$ $T_{effector}$) or perforin expression (Figures 6D, 6E, and S6B–S6E). As expected, CMV-seropositive children had higher frequencies of $V\delta 1^+$ and $CD8^+$ $T_{effector}$ cells, but

some CMV-seronegative children also had effector $V\delta 1^+$ and $CD8^+$ T cells, suggesting $V\delta 1^+$ and $CD8^+$ T cells can act as part of a coordinated adaptive immune response, which is dependent on antigen exposure. In contrast, $V\gamma 9^+V\delta 2^+$ T cells in healthy children were perforin positive regardless of $V\delta 1^+$ or $CD8^+$ $T_{effector}$ cell levels or CMV status (Figures S6F and S6G).

DISCUSSION

Evidence is emerging that an adaptive immune paradigm underpins the function of human $\gamma\delta$ T cell subsets, including $V\delta 1^+$ (Davey et al., 2017, 2018a; Ravens et al., 2017; von Borstel et al., 2021) and $V\gamma 9^{neg}V\delta 2^+$ T cells (Davey et al., 2018b, 2018c), both in PB and at least some solid tissues (Davey et al., 2018b; Hunter et al., 2018). Such adaptive biology likely impacts both anti-viral (Davey et al., 2018b; Dechanet et al., 1999; Ravens et al., 2017) and anti-parasite (Rutishauser et al., 2020; von Borstel et al., 2021) immunity and autoimmune responses (Hohlfeld et al., 1991; Mayassi et al., 2019; Pluschke et al., 1992). In contrast, $V\gamma 9^+V\delta 2^+$ lymphocytes predominant in PB (Davey et al., 2018b; Willcox et al., 2018), and likely intestinal $V\gamma 4^+$ T cells (Mayassi et al., 2019; Melandri et al., 2018), appear to be more innate-like. Although some functional and clono/phenotypic changes have been observed during adaptive $\gamma\delta$ T cell differentiation, its transcriptional and epigenetic basis (factors affecting chromatin accessibility), and how this compares with conventional $\alpha\beta$ T cell differentiation and innate-like $\gamma\delta$ T cell subsets, has remained unclear. Here, we used a multi-pronged approach to address this question.

Single-cell methods showed that, in adult PB, most $V\delta 1^+$ lymphocytes in the majority of healthy donors occupy one of two transcriptional states. These align closely with phenotypically distinct $V\delta 1^+$ T_{naive} and $T_{effector}$ subtypes defined previously, which differentially express markers, such as CD27, IL7R α , CX3CR1, perforin, and granzyme A/B (Davey et al., 2017, 2018a), and exhibit differential chromatin accessibility. Our data reveal close transcriptional parallels with conventional $\alpha\beta$ $CD8^+$ T_{naive} and $CD8^+$ T_{EMRA} subsets, to which the $V\delta 1^+$ T_{naive} and $T_{effector}$ subsets respectively exhibit phenotypic similarity (Davey et al., 2017, 2018a). There is a strong overlap in the transcription factors governing these naive/effector states in the

(B) Using the previously defined effector-naive gene list based on shared differentially expressed transcripts (1,150-gene list) between $V\delta 1^+$ and $CD8^+$ populations, $V\gamma 9^+V\delta 2^+$ cells were hierarchically clustered with the other effector populations. The dendrogram shown places $V\delta 2^+$ cells on the effector “arm,” suggesting more similar expression of these genes. Full heatmap in Figure S4A.

(C) $V\gamma 9^+V\delta 2^+$ cells segregated with the effector compartment based on a bespoke gene set of cytotoxic markers and were hierarchically clustered. Colors for the cell populations are taken from (A). Genes are plotted row-wise and scaled to represent Z scores across samples.

(D) Cytokine production by $V\gamma 9^+V\delta 2^+$ cells in total gated $CD3^+$ T cells after 4 h PMA/ionomycin treatment. Flow plots are representative of three donors. Graphs depict mean \pm SEM of an extended set of cytokine protein expression by intracellular flow cytometry.

(E) Differential gene expression between $V\gamma 9^+V\delta 2^+$ and $V\delta 1^+$ $T_{effector}$ cells revealed close transcriptomic similarity, with 69 genes significantly differentially expressed ($p < 0.05$). Transcripts were ordered according to p value, with the most significant being *RASGRF2*, *IL12RB2*, and *SPTSSB*. A positive log fold change indicates an enrichment in $V\gamma 9^+V\delta 2^+$ cells.

(F) $V\gamma 9^+V\delta 2^+$ T cells exhibit a unique innate-like effector program. Prevalence of $\gamma\delta$ T cell subsets expressing PLZF, NKG2A, and CXCR3 was determined using flow cytometry. The top panel shows representative histograms for flow cytometric analysis; the lower panel shows bar charts representing data from five donors. Data were compared with one-way ANOVA with Tukey’s multiple comparisons ($*p < 0.05$, $**p < 0.01$). Only significant comparisons are shown.

(G) Comparison of $V\gamma 9^+V\delta 2^+$ T cell phenotype in cord blood, from unrelated children under 3 years of age, and from adult donors over 20 years of age.

(H) Quantitation of MFI levels from (G), three samples of cord blood, five samples from children under the age of 3 years, and from three adult donors. Data were analyzed by two-way ANOVA with Sidak’s multiple comparisons ($*p < 0.05$, $**p < 0.01$). Only significant comparisons are shown.




Figure 6. Adaptive differentiation of human $\gamma\delta$ T cells *in vivo*

(A) Transition of $V\gamma 9^+V\delta 1^+$ T cells to a $T_{effector}$ transcriptional program following CMV infection after kidney transplantation involving increased Eomes⁺, HOBIT⁺, and granzyme B⁺ $T_{effector}$ cells.

(B) $V\gamma 9^{neg}V\delta 2^+$ T cells transition from a predominantly CD27^{hi}, T-bet^{neg}, HOBIT^{neg}, BLIMP-1^{neg} phenotype to a CD27^{lo/neg}, T-bet⁺, HOBIT⁺, BLIMP-1⁺ phenotype 39 weeks post-CMV infection.

(C) Transition of $V\delta 1^+$ T cells from a T_{naive} to a $T_{effector}$ transcriptional program following consecutive controlled human malaria challenge (CHMI) in two malaria-naive individuals. (Left panel) Flow cytometry plots from one individual showing baseline (malaria naive), CHMI challenge 1 + 20 days after first infection and CHMI

(legend continued on next page)

V δ 1⁺ and CD8⁺ compartments. Naive V δ 1⁺ and CD8⁺ T cells are discriminated by TCF7/LEF1 expression, previously highlighted as crucial for CD8⁺ identity (Xing et al., 2016). The V δ 1⁺ T_{effector} and CD8⁺ T_{EMRA} state is distinguished by upregulation of Eomes, T-bet, and BLIMP-1, all critical to T cell effector program maintenance (Fu et al., 2017; Henning et al., 2018; Kaech and Cui, 2012; Lazarevic et al., 2013; Vieira Braga et al., 2015). V δ 1⁺ T_{effector} and CD8⁺ T_{EMRA} transcriptomes were especially closely matched, with a majority of genes increased in V δ 1⁺ T_{effector} cells versus T_{naive} cells also increased in CD8⁺ T_{EMRA} versus T_{naive} cells, reflecting upregulation of pathways such as cytotoxicity and IFN- γ production. Co-expression of HOBIT alongside T-bet/Eomes, as observed in V δ 1⁺ T_{effector} cells, is a feature of long-lived CD8⁺ T cells contributing to immunity to persistent viruses that periodically reactivate (Vieira Braga et al., 2015) and Eomes expression in CD8⁺ T cells favors long-term persistence and effector memory function (Kaech and Cui, 2012).

Conserved regulation by such critical transcription factors and involving similar downstream effector pathways strongly suggests that V δ 1⁺ T cells undergo “transcriptional reprogramming” upon differentiation from T_{naive} to T_{effector} status, analogous to CD8⁺ T cells. This transition likely applies to a second adaptive-like subset, V γ 9^{neg}V δ 2⁺ T cells (Davey et al., 2018b), and may be a general feature of human adaptive $\gamma\delta$ T cell differentiation. This common differentiation program suggests that PB V δ 1⁺ T_{effector} subsets may respond to intracellular pathogens, such as persistent viruses, using effector functions analogous to CD8⁺ T cells. Our results suggest that, in children, adaptive $\gamma\delta$ subsets may often operate in parallel with adaptive CD8⁺ arms. However, such adaptive $\gamma\delta$ T cell populations likely complement conventional $\alpha\beta$ T cell responses by providing an alternative, MHC-unrestricted immune surveillance arm that may be particularly significant in certain recurrent or chronic pathogen infections, and conceivably tumor immunosurveillance. Consistent with this, genes involved in regulating thresholds for TCR/peptide MHC recognition signaling thresholds were among the rare genes differentially expressed between the V δ 1⁺ T_{effector} and CD8⁺ T_{EMRA} subsets, with CD5, THEMIS, and SET1 all enriched in CD8 T_{EMRA} cells.

Despite similarities between V δ 1⁺ T cell and CD8⁺ T cell differentiation, we note some differences. Firstly, V δ 1⁺ T_{naive} and CD8⁺ T_{naive} subsets clearly exhibit greater differences than is evident between V δ 1⁺ and CD8⁺ T_{effector}/T_{EMRA} subsets, which are exceedingly concordant. These include an enhanced level of some NKR transcripts in V δ 1⁺ T_{naive} cells relative to CD8⁺ T_{naive} cells. Understanding the transcriptional, epigenetic, and functional significance of this is a key future aim, and may clarify signals that trigger V δ 1⁺ T_{naive} to T_{effector} cell differentiation. Secondly, V δ 1⁺ lymphocytes clustered into only two subpopulations, whereas CD8⁺ T cells adopt several phenotypically distinct memory states. This may denote a fundamental difference in differentiation, or may alternatively reflect our study’s limitations.

A striking feature of several transcription factors differentially expressed between V δ 1⁺ T_{naive} and T_{effector} subsets is their strong regulation by TCR triggering in CD8⁺ T cells. TCF7/LEF1 is lost from CD8⁺ T_{naive} cells upon TCR-dependent antigenic stimulation and priming (Willinger et al., 2006), and T-bet and Eomes are upregulated upon TCR signaling in CD8⁺ T cells, with amplification via cytokine receptor signaling (Kaech and Cui, 2012). Several observations suggest that adaptive $\gamma\delta$ T cell differentiation is similarly driven or initiated by TCR triggering. Firstly, BLIMP-1, T-bet, and Eomes upregulation in T_{naive} V δ 1⁺ cells was dependent on CD3 stimulation, consistent with $\gamma\delta$ TCR ligation triggering upregulation of transcription factors linked to the T_{effector} state. These findings were mirrored in CD8⁺ $\alpha\beta$ T cells, and HOBIT was upregulated on neither V δ 1⁺ nor CD8⁺ T_{naive} populations, consistent with its discordant regulation relative to BLIMP-1 after antigen stimulation (Kragten et al., 2018). Given the long duration of this assay, such CD3-driven upregulation of T_{effector} transcription factors may result from either direct signaling downstream of the TCR, or indirect effects, such as TCR-triggered cytokine production, or a combination of both. Secondly, the T_{naive} to T_{effector} transition is tightly linked to clonotypic expansion: consistent with single-cell data presented here, both V δ 1⁺ and V γ 9^{neg}V δ 2⁺ T_{naive} cells are clonotypically diverse and unfocused, whereas clonally expanded TCRs are only detected in T_{effector} subsets (Davey et al., 2017, 2018b). Finally, in CMV and malaria infection models, pathogen exposure elicited V δ 1⁺ (and for CMV also V γ 9^{neg}V δ 2⁺) clonal expansions (Davey et al., 2018b, 2018c; Ravens et al., 2017; Rutishauser et al., 2020; von Borstel et al., 2021), and drove phenotypic differentiation (Davey et al., 2018b, 2018c; Rutishauser et al., 2020; von Borstel et al., 2021). Collectively, these observations suggest that, as for conventional $\alpha\beta$ T cells, cognate $\gamma\delta$ TCR antigen recognition plays a critical role in triggering adaptive $\gamma\delta$ T cell differentiation. The fact that T_{effector} populations display upregulated and expedited cytotoxicity/cytokine secretion relative to T_{naive} cells, retain CD3/TCR sensitivity, and exhibit long-term persistence *in vivo*, suggests ongoing potential for $\gamma\delta$ TCR ligand recognition during secondary/tertiary responses.

Previous studies on transcriptional regulation of T cell differentiation have focused largely on conventional $\alpha\beta$ T cells. This study outlines comprehensively the transcriptional basis for adaptive $\gamma\delta$ T cell biology. The results are in accordance with, but extend substantially, our previous work on V δ 1⁺ T_{naive} and T_{effector} cells (Davey et al., 2017, 2018a). These studies established phenotypic and clonotypic changes consistent with some kind of adaptive differentiation, but did not define underlying transcriptional paradigms and their alignment with conventional $\alpha\beta$ T cell differentiation. Many previous studies have assessed V δ 1⁺ T cells *en masse*, an example being Gutierrez-Arcelus et al. (2019), which positioned V δ 1⁺ T cells on an “innateness gradient.” In light of our results, caution should be exerted in such interpretations, as factors such as age and infectious status heavily influence the balance between T_{naive} and T_{effector} V δ 1⁺

challenge 3 + 20 days and measure expression of T-bet, HOBIT, and Eomes versus CD27. (Right panel) Frequencies of T-bet⁺, HOBIT⁺, and Eomes⁺ V δ 1⁺ T cells from the same individual and second individual undergoing CHMI.

(D) Assessment of V δ 1⁺ T_{effector} (CD27^{lo/neg}) and CD8⁺ effector (T_{CM} + T_{EM} + T_{EMRA}) cells in 16 healthy children (aged 12 months to 12 years).

(E) Percentage of CD27^{lo/neg} V δ 1⁺ cells correlates with percentage of CD8⁺ effector $\alpha\beta$ T cells (R² = 0.76, Spearman coefficient = 0.73, p = 0.0017).

populations and are major confounding factors, limiting the utility and validity of such a gradient; the innateness scale proposed is also likely to overlap largely with effector program signatures. Also, expression of markers, such as NKG2D, on $V\delta 1^+$ T cells is sometimes interpreted as denoting an innate-like biology (Wu et al., 2019), whereas NKG2D is upregulated on both $V\delta 1^+$ $T_{effector}$ and $CD8^+$ T_{EMRA} cells, and may alternatively reflect the presence of adaptive $V\delta 1^+$ $T_{effector}$ populations.

Our results confirm that, relative to adaptive subsets, $V\gamma 9^+V\delta 2^+$ T cells adopt a fundamentally different and innate-like immunobiology. Unlike $V\delta 1^+$ T cells, the adult $V\gamma 9^+V\delta 2^+$ T cell subset lacked a distinct T_{naive} subpopulation devoid of effector markers, and universally expressed T-bet and Eomes. The transcriptional profile of $V\gamma 9^+V\delta 2^+$ T cells unmistakably denoted a type of $T_{effector}$ status based on expression of granzyme A/B, perforin, and T-bet/Eomes. However, elements of this profile were notably different from both $V\delta 1^+$ and $CD8^+$ $T_{effector}$ cells, including expression of PLZF, a transcription factor linked with innate-like T cells (Fergusson et al., 2014; Kovalovsky et al., 2008; Kreslavsky et al., 2009; Savage et al., 2008), NKG2A and GZMK, both expressed by NK cells (Bratke et al., 2005; Brooks et al., 1997), and distinct cytokine and chemokine receptor expression patterns. A caveat is that we assessed $V\gamma 9^+V\delta 2^+$ T cells *en masse*, whereas some other studies (Ryan et al., 2016; Wragg et al., 2020) have defined phenotypically distinct subsets present in multiple individuals. The central memory phenotype of $V\gamma 9^+V\delta 2^+$ T cells present in most donors is consistent with profiles observed by Ryan et al. (2016); we observe NKG2A expression on most $V\gamma 9^+V\delta 2^+$ cells in all donors, consistent with Wragg et al.'s findings (2020). Also, we observe markers linked with innate-like T cells (e.g., NKG2A, PLZF, C/EBP δ), consistent with previous work (Gutierrez-Arcelus et al., 2019), which indicated similarities between $V\gamma 9^+V\delta 2^+$, MAIT, and iNKT transcriptional profiles. While we did not directly compare NK transcriptional profiles, Pizzolato et al. (2019) detected a subpopulation of $\gamma\delta$ T cells clustering with NK cells and this may align with the $V\gamma 9^+V\delta 2^+$ subset. In contrast to $V\delta 1^+$ T cells, our results suggest a predisposition to effector status from birth and maturation early in life, since $V\gamma 9^+V\delta 2^+$ T cell expression of Eomes and HOBIT was evident in cord blood, and universal by <3 years, consistent with recent findings (Papadopoulou et al., 2020). Such an innate-like paradigm is likely facilitated by the semi-invariant $V\gamma 9^+V\delta 2^+$ TCR repertoire present from birth, featuring prevalence of public $V\gamma 9^+$ clonotypes (Davey et al., 2018b; Willcox et al., 2018). While our results support post-natal maturation of $V\gamma 9^+V\delta 2^+$ T cells (Ryan et al., 2016; Wragg et al., 2020), they also suggest that, from early life onward, changes reflect modification of an innate-effector transcriptional profile/phenotype, rather than ongoing potential for the more radical transcriptional reprogramming that applies to adaptive $\gamma\delta$ T cell subsets.

In summary, we show that certain $\gamma\delta$ T cell subsets can, throughout life and in response to specific immunological stimuli, undergo adaptive “transcriptional reprogramming” akin to changes in $CD8^+$ T cells upon antigen-induced differentiation. This paradigm applies to $V\delta 1^+$ T cells present in PB and diverse tissues (Davey et al., 2017, 2018a; Hunter et al., 2018; Ravens et al., 2017) and the less prevalent $V\gamma 9^{neg}V\delta 2^+$ subset (Davey

et al., 2018b, 2018c). We suggest that adaptive differentiation drives inflammatory/cytotoxic $\gamma\delta$ T cell responses to specific immune challenges in diverse biological scenarios. These likely include beneficial responses to pathogen infection (Davey et al., 2018a, 2018c), including CMV (Davey et al., 2018b; Ravens et al., 2017), EBV (Farnault et al., 2013; Fujishima et al., 2007), and malaria (Rutishauser et al., 2020; von Borstel et al., 2021). They likely complement conventional adaptive $\alpha\beta$ T cell immunity, by permitting pathogen-specific responses to microenvironmental niches with compromised MHC expression, either resulting from viral immune evasion (for CMV and EBV), infection of cells devoid of MHC (e.g., red blood cells in the case of *P. falciparum*), or conceivably class I MHC loss during tumor development and immune evasion. However, adaptive $\gamma\delta$ responses may sometimes promote immunopathology, as in autoimmune myositis driven by clonotypically focused $V\gamma 9^{neg}V\delta 2^+$ T cells apparently $T_{effector}$ in phenotype (Hohlfeld et al., 1991; Pluschke et al., 1992). A recent study reported that, in coeliac disease, the intestinal IEL population is enriched with inflammatory, T-bet $^+$, clonotypically focused $V\delta 1^+$ cells that may be antigen driven, aligning with the adaptive $\gamma\delta$ T cell differentiation paradigm outlined here (Mayassi et al., 2019). Future studies will no doubt extend the relevance of this adaptive paradigm to different settings. Understanding the transcriptional regulation of $\gamma\delta$ T cell differentiation may also facilitate development of $\gamma\delta$ T cell immunotherapy approaches in infectious disease and cancer.

Limitations of the study

We highlight three study limitations. Firstly, we focus on a modest number of individuals and on a limited number of $\gamma\delta$ T cells in PB; a wider set of $V\delta 1^+$ T cell differentiation states therefore likely exist. Future studies will no doubt elaborate on our findings by exploring larger cohorts and/or cell numbers, and assessing $\gamma\delta$ T cells in diverse scenarios, including active infection, and different tissues. Consistent with this, we recently defined a tissue-resident-like hepatic $V\delta 1^+$ subset phenotypically and functionally distinct from PB subsets (Hunter et al., 2018). Secondly, we used $CD8^+$ T_{EMRA} cells as a conventional effector T cell comparator; however, more marked differences between $V\delta 1^+$ $T_{effector}$ cells and other $CD8^+$ T cell subtypes may exist; we did not directly compare transcriptional profiles of $CD4^+$ T cell populations, and alignment of $V\delta 1^+$ to $CD4^+$ T cell differentiation warrants further study. Finally, despite strong similarities between $V\delta 1^+$ and $CD8^+$ T cell subsets, our results do not exclude the possibility that, aside from MHC-unrestricted target cell recognition, adaptive $\gamma\delta$ T cell populations may exhibit substantial functional differences to conventional counterparts, such as in their dynamics or relative importance of TCR-independent regulatory axes (e.g., mediated via NKRrs).

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY

- Lead contact
- Materials availability
- Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
 - Ethical approval and samples
- **METHOD DETAILS**
 - T-cell isolation, culture, activation
 - Antibodies and flow cytometry
 - Single cell transcriptomics analysis
 - Reconstruction of $\gamma\delta$ TCR sequences from single cell RNAseq
 - Bulk RNAseq analysis
 - ATACseq analysis
 - CD3/CD28/IL-2 stimulation assays
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.celrep.2022.110858>.

ACKNOWLEDGMENTS

We thank all donors and patients who participated in the study, AMC biobank staff for provision of renal transplant patient samples, and the Anthony Nolan Cell Therapy Centre for cord blood samples. We thank Dr. Matthew McKenzie and the University of Birmingham CMDS Cell Sorting Facility for $\gamma\delta$ T cell isolation, the University of Birmingham Protein Expression Facility for use of facilities, FlowCore (Monash University) for cell sorting assistance, and the Medical Genomics facility (MHTP) for their services. We thank US CHMI study volunteers for their contribution and commitment to malaria research; Dr. Gregory Deye, of the National Institutes of Allergy and Infectious Diseases at the National Institutes of Health, for service as program medical officer of the repetitive challenge study at the University of Maryland, Baltimore (UMB); and Faith Pa'ahana-Brown, RN, Lisa Chrisley, RN, Alyson Kwon, Brenda Dorsey, Ana Raquel Da Costa, Jeffrey Crum, Kathleen Strauss, and Biraj Shrestha for their roles in the repetitive challenge study at UMB. We thank Sanaria, Inc. for providing mosquitoes for human malaria infections. The work was supported by Wellcome Trust Investigator award funding, supporting C.R.W., M.S.D., F.M., T.E.T. and M.S. (099266/Z/12/Z and 221725/Z/20/Z to B.E.W.). J.L.McM. was supported by a CRUK non-clinical studentship; F.A.V.B. by Open Targets (<https://www.opentargets.org/>); J.R. is supported by an Australian Research Council (ARC) Laureate Fellowship; K.W. and K.E.L. are supported by a National Institutes of Health (NIH), Division of Allergy and Infectious Diseases (NIAID) U01 (AI-110852), distributed by the Henry M. Jackson Foundation (no. 1701447C); and K.E.L. is further supported by additional funding from the NIAID (U01-HD092308, R01-AE141900, and AI110820-06), The Geneva Foundation (V-12VAXHRFS-03), the Medical Technology Enterprise Consortium (MTEC-17-01), and Pfizer (C4591001, site 1002). M.S.D. is supported by an ARC Discovery Early Career Researcher Award (DE200100292), Rebecca L. Cooper Medical Research Foundation Project Grant (PG2020668), and ARC Discovery Project (DP210103327). The opinions and assertions expressed herein are those of the authors and do not necessarily reflect the official policy or position of the Uniformed Services University or the Department of Defense.

AUTHOR CONTRIBUTIONS

Conceptualization, B.E.W., C.R.W., and M.S.D.; methodology, C.R.W., M.S.D., J.L.M., T.E.T., and A.v.B.; software, J.L.M.; formal analysis, J.L.M.; investigation, C.R.W., A.v.B., M.S.D., M.S., and T.E.T.; resources, E.S., G.S.T., J.R., E.B.M.R., F.J.B., F.A.V.B., X.C., S.A.T., A.A.B., K.W., K.E.L., and M.J.T.S.; data curation, J.L.M.; writing – original draft, B.E.W., C.R.W., J.L.M., M.S.D., and T.E.T.; writing – review & editing, B.E.W., C.R.W.,

J.L.M., M.S.D., and A.v.B.; visualization, C.R.W., J.L.M., F.M., M.S.D., A.v.B., and T.E.T.; funding acquisition, B.E.W. and M.S.D.

DECLARATION OF INTERESTS

M.J.T.S. has been employed by 10x Genomics since April 2018; this employment had no bearing on this work. The other authors declare no competing financial interests.

Received: September 29, 2020

Revised: February 15, 2022

Accepted: May 2, 2022

Published: May 24, 2022

REFERENCES

- Bank, I., Tanay, A., Migdal, A., Book, M., and Livneh, A. (1995). $V\gamma 9-V\delta 2+$ $\gamma\delta$ T cells from a patient with felty syndrome that exhibit aberrant response to triggering of the CD3 molecule can regulate immunoglobulin secretion by B cells. *Clin. Immunol.* *74*, 162–169.
- Bratke, K., Kuepper, M., Bade, B., Virchow, J.C., Jr., and Luttmann, W. (2005). Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. *Eur. J. Immunol.* *35*, 2608–2616.
- Broad Institute (2019). “Picard Toolkit”. In GitHub Repository. <http://broadinstitute.github.io/picard/> (Broad Institute).
- Brooks, A.G., Posch, P.E., Scorzelli, C.J., Borrego, F., and Coligan, J.E. (1997). NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. *J. Exp. Med.* *185*, 795–800.
- Buenrostro, J.D., Wu, B., Chang, H.Y., and Greenleaf, W.J. (2015). ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. *Curr Protoc Mol Biol.* *21*, 21.29.1–21.29.9.
- Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* *36*, 411–420.
- Davey, M.S., Willcox, C.R., Baker, A.T., Hunter, S., and Willcox, B.E. (2018a). Recasting human $V\delta 1$ lymphocytes in an adaptive role. *Trends Immunol.* *39*, 446–459.
- Davey, M.S., Willcox, C.R., Hunter, S., Kasatskaya, S.A., Remmerswaal, E.B.M., Salim, M., Mohammed, F., Bemelman, F.J., Chudakov, D.M., Oo, Y.H., and Willcox, B.E. (2018b). The human $V\delta 2^+$ T-cell compartment comprises distinct innate-like $V\gamma 9^+$ and adaptive $V\gamma 9^-$ subsets. *Nat. Commun.* *9*, 1760.
- Davey, M.S., Willcox, C.R., Hunter, S., Oo, Y.H., and Willcox, B.E. (2018c). $V\delta 2^+$ T cells—two subsets for the price of one. *Front. Immunol.* *9*, 2106.
- Davey, M.S., Willcox, C.R., Joyce, S.P., Ladell, K., Kasatskaya, S.A., McLaren, J.E., Hunter, S., Salim, M., Mohammed, F., Price, D.A., et al. (2017). Clonal selection in the human $V\delta 1$ T cell repertoire indicates $\gamma\delta$ TCR-dependent adaptive immune surveillance. *Nat. Commun.* *8*, 14760.
- Dechanet, J., Merville, P., Lim, A., Retiere, C., Pitard, V., Lafarge, X., Michelson, S., Meric, C., Hallet, M.M., Kourilsky, P., et al. (1999). Implication of gamma-delta T cells in the human immune response to cytomegalovirus. *J. Clin. Invest.* *103*, 1437–1449.
- Dey, K.K., Hsiao, C.J., and Stephens, M. (2017). Visualizing the structure of RNA-seq expression data using grade of membership models. *PLoS Genet.* *13*, e1006599.
- Durinck, S., Spellman, P.T., Birney, E., and Huber, W. (2009). Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* *4*, 1184–1191.
- Farnault, L., Gertner-Dardenne, J., Gondois-Rey, F., Michel, G., Chambost, H., Hirsch, I., and Olive, D. (2013). Clinical evidence implicating gamma-delta T cells in EBV control following cord blood transplantation. *Bone Marrow Transplant.* *48*, 1478–1479.

- Fergusson, J.R., Smith, K.E., Fleming, V.M., Rajoriya, N., Newell, E.W., Simons, R., Marchi, E., Bjorkander, S., Kang, Y.H., Swadling, L., et al. (2014). CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. *Cell Rep.* **9**, 1075–1088.
- Fu, G., Vallee, S., Rybakina, V., McGuire, M.V., Ampudia, J., Brockmeyer, C., Salek, M., Fallen, P.R., Hoerter, J.A.H., Munshi, A., et al. (2009). Thymic thymocyte selection through regulation of T cell antigen receptor-mediated signaling. *Nat. Immunol.* **10**, 848–856.
- Fu, S.H., Yeh, L.T., Chu, C.C., Yen, B.L.J., and Sytwu, H.K. (2017). New insights into Blimp-1 in T lymphocytes: a divergent regulator of cell destiny and effector function. *J. Biomed. Sci.* **24**, 49.
- Fujishima, N., Hirokawa, M., Fujishima, M., Yamashita, J., Saitoh, H., Ichikawa, Y., Horiuchi, T., Kawabata, Y., and Sawada, K.I. (2007). Skewed T cell receptor repertoire of Vdelta1(+) gammadelta T lymphocytes after human allogeneic haematopoietic stem cell transplantation and the potential role for Epstein-Barr virus-infected B cells in clonal restriction. *Clin. Exp. Immunol.* **149**, 70–79.
- Guinney, J., Dienstmann, R., Wang, X., de Reynies, A., Schlicker, A., Sonesson, C., Marisa, L., Roepman, P., Nyamandanda, G., Angelino, P., et al. (2015). The consensus molecular subtypes of colorectal cancer. *Nat. Med.* **21**, 1350–1356.
- Gutierrez-Arcelus, M., Teslovich, N., Mola, A.R., Polidoro, R.B., Nathan, A., Kim, H., Hannes, S., Slowikowski, K., Watts, G.F.M., Korsunsky, I., et al. (2019). Lymphocyte innateness defined by transcriptional states reflects a balance between proliferation and effector functions. *Nat. Commun.* **10**, 687.
- Hayday, A.C. (2000). [gamma] [delta] cells: a right time and a right place for a conserved third way of protection. *Annu. Rev. Immunol.* **18**, 975–1026.
- Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., Singh, H., and Glass, C.K. (2010). Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* **38**, 576–589.
- Henning, A.N., Roychoudhuri, R., and Restifo, N.P. (2018). Epigenetic control of CD8(+) T cell differentiation. *Nat. Rev. Immunol.* **18**, 340–356.
- Hohlfeld, R., Engel, A.G., Li, K., and Harper, M.C. (1991). Polymyositis mediated by T lymphocytes that express the gamma/delta receptor. *N. Engl. J. Med.* **324**, 877–881.
- Hunter, S., Willcox, C.R., Davey, M.S., Kasatskaya, S.A., Jeffery, H.C., Chudakov, D.M., Oo, Y.H., and Willcox, B.E. (2018). Human liver infiltrating $\gamma\delta$ T cells are composed of clonally expanded circulating and tissue-resident populations. *J. Hepatol.* **69**, 654–665.
- Kaech, S.M., and Cui, W. (2012). Transcriptional control of effector and memory CD8+ T cell differentiation. *Nat. Rev. Immunol.* **12**, 749–761.
- Kaminski, H., Menard, C., El Hayani, B., Adjibabi, A.N., Marseres, G., Courant, M., Zouine, A., Pitard, V., Garrigue, I., Burrel, S., et al. (2020). Characterization of a unique gammadelta T cell subset as a specific marker of CMV infection severity. *J. Infect. Dis.* **223**, 655–666.
- Karunakaran, M.M., Willcox, C.R., Salim, M., Paletta, D., Fichtner, A.S., Noll, A., Starick, L., Nohren, A., Begley, C.R., Berwick, K.A., et al. (2020). Butyrophilin-2A1 directly binds germline-encoded regions of the V γ 9V δ 2 TCR and is essential for phosphoantigen sensing. *Immunity* **52**, 487–498.e6.
- Kauffmann, A., Gentleman, R., and Huber, W. (2009). arrayQualityMetrics—a bioconductor package for quality assessment of microarray data. *Bioinformatics* **25**, 415–416.
- Kim, D., Langmead, B., and Salzberg, S.L. (2015). HISAT: a fast spliced aligner with low memory requirements. *Nat. Methods* **12**, 357–360.
- Koay, H.F., Su, S., Amann-Zalcenstein, D., Daley, S.R., Comerford, I., Miosge, L., Whyte, C.E., Konstantinov, I.E., d’Udekem, Y., Baldwin, T., et al. (2019). A divergent transcriptional landscape underpins the development and functional branching of MAIT cells. *Sci. Immunol.* **4**, eaay6039.
- Kovalovsky, D., Uche, O.U., Eladad, S., Hobbs, R.M., Yi, W., Alonzo, E., Chua, K., Eidson, M., Kim, H.J., Im, J.S., et al. (2008). The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. *Nat. Immunol.* **9**, 1055–1064.
- Kragten, N.A.M., Behr, F.M., Vieira Braga, F.A., Remmerswaal, E.B.M., Weselink, T.H., Oja, A.E., Hombrink, P., Kallies, A., van Lier, R.A.W., Stark, R., and van Gisbergen, K.P.J.M. (2018). Blimp-1 induces and Hobit maintains the cytotoxic mediator granzyme B in CD8 T cells. *Eur. J. Immunol.* **48**, 1644–1662.
- Kreslavsky, T., Savage, A.K., Hobbs, R., Gounari, F., Bronson, R., Pereira, P., Pandolfi, P.P., Bendelac, A., and von Boehmer, H. (2009). TCR-inducible PLZF transcription factor required for innate phenotype of a subset of gammadelta T cells with restricted TCR diversity. *Proc. Natl. Acad. Sci. U S A* **106**, 12453–12458.
- Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**, 357–359.
- Law, C.W., Chen, Y., Shi, W., and Smyth, G.K. (2014). voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol.* **15**, R29.
- Lazarevic, V., Glimcher, L.H., and Lord, G.M. (2013). T-bet: a bridge between innate and adaptive immunity. *Nat. Rev. Immunol.* **13**, 777–789.
- Lee, C.H., Zhang, H.H., Singh, S.P., Koo, L., Kabat, J., Tsang, H., Singh, T.P., and Farber, J.M. (2018). C/EBP δ drives interactions between human MAIT cells and endothelial cells that are important for extravasation. *eLife* **7**, e32532.
- Lefranc, M.P., Giudicelli, V., Ginestoux, C., Jabado-Michaloud, J., Folch, G., Bellahcene, F., Wu, Y., Gemrot, E., Brochet, X., Lane, J., et al. (2009). IMGT, the international ImMunoGeneTics information system. *Nucleic Acids Res.* **37**, D1006–D1012.
- Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Subgroup (2009). The sequence alignment/map format and SAMtools. *Bioinformatics* **25**, 2078–2079.
- Liao, Y., Smyth, G.K., and Shi, W. (2013). The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. *Nucleic Acids Res.* **41**, e108.
- Maier, E., Hebenstreit, D., Posselt, G., Hammerl, P., Duschl, A., and Horejs-Hoeck, J. (2011). Inhibition of suppressive T cell factor 1 (TCF-1) isoforms in naive CD4+ T cells is mediated by IL-4/STAT6 signaling. *J. Biol. Chem.* **286**, 919–928.
- Martins, G.A., Cimmino, L., Shapiro-Shelef, M., Szabolcs, M., Herron, A., Magnusdottir, E., and Calame, K. (2006). Transcriptional repressor Blimp-1 regulates T cell homeostasis and function. *Nat. Immunol.* **7**, 457–465.
- Mayassi, T., Ladell, K., Gudjonson, H., McLaren, J.E., Shaw, D.G., Tran, M.T., Rokicka, J.J., Lawrence, I., Grenier, J.C., van Unen, V., et al. (2019). Chronic inflammation permanently reshapes tissue-resident immunity in celiac disease. *Cell* **176**, 967–981.e19.
- McCarthy, D.J., Chen, Y., and Smyth, G.K. (2012). Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. *Nucleic Acids Res.* **40**, 4288–4297.
- Melandri, D., Zlatavara, I., Chaleil, R.A.G., Dart, R.J., Chancellor, A., Nussbaumer, O., Polyakova, O., Roberts, N.A., Wesch, D., Kabelitz, D., et al. (2018). The $\gamma\delta$ TCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. *Nat. Immunol.* **19**, 1352–1365.
- Oberdoerffer, S., Moita, L.F., Neems, D., Freitas, R.P., Hacohen, N., and Rao, A. (2008). Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein, hnRNPL. *Science* **321**, 686–691.
- Ono, K., Muetze, T., Kolishovski, G., Shannon, P., and Demchak, B. (2015). CyREST: turbocharging cytoscape access for external tools via a RESTful API. *F1000Research* **4**, 478.
- Papadopoulou, M., Dimova, T., Shey, M., Briel, L., Veldtsman, H., Khomba, N., Africa, H., Steyn, M., Hanekom, W.A., Scriba, T.J., et al. (2020). Fetal public V γ 9V δ 2 T cells expand and gain potent cytotoxic functions early after birth. *Proc. Natl. Acad. Sci. U S A* **117**, 18638–18648.
- Parker, C.M., Groh, V., Band, H., Porcelli, S.A., Morita, C., Fabbri, M., Glass, D., Strominger, J.L., and Brenner, M.B. (1990). Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. *J. Exp. Med.* **171**, 1597–1612.
- Patro, R., Duggal, G., Love, M.I., Irizarry, R.A., and Kingsford, C. (2017). Salmon provides fast and bias-aware quantification of transcript expression. *Nat. Methods* **14**, 417–419.

- Picelli, S., Faridani, O.R., Björklund, A.K., Winberg, G., Sagasser, S., and Sandberg, R. (2014). Full-length RNA-seq from single cells using Smart-seq2. *Nat. Protoc.* **9**, 171–181.
- Pizzolato, G., Kaminski, H., Tosolini, M., Franchini, D.M., Pont, F., Martins, F., Valle, C., Labourdette, D., Cadot, S., Quillet-Mary, A., et al. (2019). Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRV δ 1 and TCRV δ 2 $\gamma\delta$ T lymphocytes. *Proc. Natl. Acad. Sci. U S A* **116**, 11906–11915.
- Pluschke, G., Ruegg, D., Hohlfeld, R., and Engel, A.G. (1992). Autoaggressive myocytotoxic T lymphocytes expressing an unusual gamma/delta T cell receptor. *J. Exp. Med.* **176**, 1785–1789.
- Ravens, S., Schultze-Florey, C., Raha, S., Sandrock, I., Drenker, M., Oberdorfer, L., Reinhardt, A., Ravens, I., Beck, M., Geffers, R., et al. (2017). Human $\gamma\delta$ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. *Nat. Immunol.* **18**, 393–401.
- Rigau, M., Ostrouska, S., Fulford, T.S., Johnson, D.N., Woods, K., Ruan, Z., McWilliam, H.E.G., Hudson, C., Tutuka, C., Wheatley, A.K., et al. (2020). Butyrophilin 2A1 is essential for phosphoantigen reactivity by $\gamma\delta$ T cells. *Science* **367**, eaay5516.
- Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015). Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47.
- Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140.
- Rutishauser, T., Lepore, M., Di Blasi, D., Dangy, J.P., Abdulla, S., Jongo, S., Ramadhani, K., Sim, B.K.L., Hoffman, S.L., Tanner, M., et al. (2020). Activation of TCR V δ 1⁺ and V δ 1⁺V δ 2⁺ $\gamma\delta$ T cells upon controlled infection with *Plasmodium falciparum* in Tanzanian volunteers. *J. Immunol.* **204**, 180–191.
- Ryan, P.L., Sumaria, N., Holland, C.J., Bradford, C.M., Izotova, N., Grandjean, C.L., Jawad, A.S., Bergmeier, L.A., and Pennington, D.J. (2016). Heterogeneous yet stable V δ 2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals. *Proc. Natl. Acad. Sci. U S A* **113**, 14378–14383.
- Savage, A.K., Constantinides, M.G., Han, J., Picard, D., Martin, E., Li, B., Lantz, O., and Bendelac, A. (2008). The transcription factor PLZF directs the effector program of the NKT cell lineage. *Immunity* **29**, 391–403.
- Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* **13**, 2498–2504.
- Siegers, G.M., Barreira, C.R., Postovit, L.M., and Dekaban, G.A. (2017). CD11d β 2 integrin expression on human NK, B, and $\gamma\delta$ T cells. *J. Leukoc. Biol.* **101**, 1029–1035.
- Silva-Santos, B., Mensurado, S., and Coffelt, S.B. (2019). $\gamma\delta$ T cells: pleiotropic immune effectors with therapeutic potential in cancer. *Nat. Rev. Cancer* **19**, 392–404.
- Simeoni, L., Posevitz, V., Kolsch, U., Meinert, I., Bruyns, E., Pfeiffer, K., Reinhold, D., and Schraven, B. (2005). The transmembrane adapter protein SIT regulates thymic development and peripheral T-cell functions. *Mol. Cell. Biol.* **25**, 7557–7568.
- Stubbington, M.J.T., Lonnberg, T., Proserpio, V., Clare, S., Speak, A.O., Dougan, G., and Teichmann, S.A. (2016). T cell fate and clonality inference from single-cell transcriptomes. *Nat. Methods* **13**, 329–332.
- Taddy, M. (2012). On estimation and selection for topic models. *Proceedings of the Fifteenth International Conference on Artificial Intelligence and Statistics*. In *Proceedings of Machine Learning Research*, PMLR, D.L. Neil and G. Mark, eds., pp. 1184–1193.
- Tan, L., Fichtner, A.S., Bubke, A., Odak, I., Schultze-Florey, C., Koenecke, C., Förster, R., Jarek, M., von Kaisenberg, C., Borchers, A., et al. (2020). A fetal wave of human type-3 $\gamma\delta$ T cells with restricted TCR diversity persists into adulthood. Preprint at bioRxiv. <https://doi.org/10.1101/2020.08.14.248146>.
- Team, R.C. (2000). R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing). <https://www.R-project.org/>.
- Vantourout, P., and Hayday, A. (2013). Six-of-the-best: unique contributions of $\gamma\delta$ T cells to immunology. *Nat. Rev. Immunol.* **13**, 88–100.
- Vieira Braga, F.A., Hertoghs, K.M.L., Kragten, N.A.M., Doody, G.M., Barnes, N.A., Remmerswaal, E.B.M., Hsiao, C.C., Moerland, P.D., Wouters, D., Derks, I.A.M., et al. (2015). Blimp-1 homolog Hobit identifies effector-type lymphocytes in humans. *Eur. J. Immunol.* **45**, 2945–2958.
- Voisinne, G., Gonzalez de Peredo, A., and Roncagalli, R. (2018). CD5, an undercover regulator of TCR signaling. *Front. Immunol.* **9**, 2900.
- von Borstel, A., Chevour, P., Arsovski, D., Krol, J.M.M., Howson, L.J., Berry, A.A., Day, C.L., Ogongo, P., Ernst, J.D., Nomicos, E.Y.H., et al. (2021). Repeated *Plasmodium falciparum* infection in humans drives the clonal expansion of an adaptive $\gamma\delta$ T cell repertoire. *Sci. Transl. Med.* **13**, eaab7430.
- Warnes, G.R., Bolker, B., Bonebakker, L., Gentleman, R., Huber, W., Liaw, A., Lumley, T., Maechler, M., Magnusson, A., Moeller, S., et al. (2020). Gplots: Various R Programming Tools for Plotting Data. R package version 3.1.1.
- Willcox, B.E., and Willcox, C.R. (2019). $\gamma\delta$ TCR ligands: the quest to solve a 500-million-year-old mystery. *Nat. Immunol.* **20**, 121–128.
- Willcox, C.R., Davey, M.S., and Willcox, B.E. (2018). Development and selection of the human V γ 9V δ 2⁺ T-cell repertoire. *Front. Immunol.* **9**, 1501.
- Willcox, C.R., Mohammed, F., and Willcox, B.E. (2020). The distinct MHC-unrestricted immunobiology of innate-like and adaptive-like human gamma delta T cell subsets-Nature's CAR-T cells. *Immunol. Rev.* **298**, 25–46.
- Willcox, C.R., Vantourout, P., Salim, M., Zlatareva, I., Melandri, D., Zanardo, L., George, R., Kjaer, S., Jeeves, M., Mohammed, F., et al. (2019). Butyrophilin-like 3 directly binds a human V γ 4⁺ T cell receptor using a modality distinct from clonally-restricted antigen. *Immunity* **51**, 813–825.e4.
- Willinger, T., Freeman, T., Herbert, M., Hasegawa, H., McMichael, A.J., and Callan, M.F.C. (2006). Human naive CD8 T cells down-regulate expression of the WNT pathway transcription factors lymphoid enhancer binding factor 1 and transcription factor 7 (T cell factor-1) following antigen encounter in vitro and in vivo. *J. Immunol.* **176**, 1439–1446.
- Wragg, K.M., Tan, H.X., Kristensen, A.B., Nguyen-Robertson, C.V., Kelleher, A.D., Parsons, M.S., Wheatley, A.K., Berzins, S.P., Pellicci, D.G., Kent, S.J., and Juno, J.A. (2020). High CD26 and low CD94 expression identifies an IL-23 responsive V δ 2⁺ T cell subset with a MAIT cell-like transcriptional profile. *Cell Rep.* **31**, 107773.
- Wu, Y., Kyle-Cezar, F., Woolf, R.T., Naceur-Lombardelli, C., Owen, J., Biswas, D., Lorenc, A., Vantourout, P., Gazinska, P., Grigoriadis, A., et al. (2019). An innate-like V δ 1⁺ $\gamma\delta$ T cell compartment in the human breast is associated with remission in triple-negative breast cancer. *Sci. Transl. Med.* **11**, eaax9364.
- Xing, S., Li, F., Zeng, Z., Zhao, Y., Yu, S., Shan, Q., Li, Y., Phillips, F.C., Maina, P.K., Qi, H.H., et al. (2016). Tcf1 and Lef1 transcription factors establish CD8(+) T cell identity through intrinsic HDAC activity. *Nat. Immunol.* **17**, 695–703.
- Zhang, Y., Liu, T., Meyer, C.A., Eickhout, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., and Liu, X.S. (2008). Model-based analysis of ChIP-seq (MACS). *Genome Biol.* **9**, R137.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-human CD3, clone UCHT1	Biolegend	Cat# 300460
TCR $\alpha\beta$, clone IP26	ThermoFisher	Cat#535531
TCR V δ 1, clone REA173	Miltenyi	Cat#130-118-362
TCR V δ 2, clone 123R3	Miltenyi	Cat#130-095-796
TCR V γ 9, clone IMMU360	Beckman Coulter	Cat#A63663
CD27, clone M-T271	Biolegend	Cat#356422
CD45RA, clone HI100	Biolegend	Cat# 304151
CXCR3, clone GO25H7	Biolegend	Cat#353705
CX ₃ CR1, clone 2A9-1	Biolegend	Cat#341626
CD127, clone A019D5	Biolegend	Cat#351334
CD45RO, clone UCHL1	Biolegend	Cat# 304237
CD161, clone HP-3G10	Biolegend	Cat# 339903
NKG2A, clone Z199	Beckman Coulter	Cat#A60797
Granzyme A, clone CB9	Biolegend	Cat#507204
Granzyme B, clone GB11	Biolegend	Cat#515403
Perforin, clone B-D48	Biolegend	Cat#353305
TCF-7, clone 7F11A19	Biolegend	Cat#655203
EOMES, clone WD1928	ThermoFisher	Cat #50-4877-42
Blimp-1, clone 6D3	BD Biosciences	Cat#565276
Hobit, clone Sanquin-Hobit/1	BD Biosciences	Cat#566250
T-bet, clone eBio4B10	ThermoFisher	Cat#12-5825-82
PLZF, clone 21F7	ThermoFisher	Cat#12-9320-82
IFN γ , clone 4S.B3	Biolegend	Cat#502511
TNF α , clone mAb11	Biolegend	Cat#502935
CCL5, clone VL1	Biolegend	Cat#515503
IL-2, clone MQ1-17H12	Biolegend	Cat#500347
IL-17A, clone BL168	Biolegend	Cat#512315
GM-CSF, clone BVD2-21C11	Biolegend	Cat#502305
CD19, clone HIB19	TONBO biosciences	Cat#20-0199-T100
CD14, clone 61D3	TONBO biosciences	Cat#20-0149-T100
CD3, clone OKT-3	Biolegend	Cat#317326
Biological samples		
Healthy donor peripheral blood mononuclear cells		This study
Chemicals, peptides, and recombinant proteins		
Triton X-100	Sigma	Cat#X100
recombinant RNase inhibitor	Takara Bio	Cat#2313A
RNAlater	Sigma	Cat #R0901
digitonin	Promega	Cat# G9441
Recombinant IL-2	Peptotech	Cat# 200-02
RPMI-1640	ThermoFisher	Cat#21875034
L-Glutamine	ThermoFisher	Cat#25030081
Sodium pyruvate	ThermoFisher	Cat#11360070
penicillin/streptomycin	ThermoFisher	Cat#15070063

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Fetal Calf serum	Sigma	Cat#F7524
Permeabilisation Buffer	ThermoFisher	Cat#00-8333-56
PMA	Sigma	Cat#P1585
Ionomycin	Sigma	Cat#I0634
Brefeldin A	ThermoFisher	Cat#00-4506-51
Monensin	BD Biosciences	Cat#554724

Critical commercial assays

SmartScribe Reverse Transcriptase	Takara Bio	Cat#639538
KAPA HiFi Hot Start Ready Mix	Fisher Scientific	Cat#50-196-5217
Nextera XT kit	Illumina	Cat#CFC-131-1024
RNeasy Plus Micro kit	Qiagen	Cat#74034
Nextera DNA Library Prep Kit	Illumina	Cat#FC-121-1030
NextSeq 500/550 High Output kit v2.5	Illumina	Cat#20024907
EasySep Human APC Selection Kit	Stemcell Technologies	Cat#17661

Deposited data

Epigenetic and transcriptional profiling of human gamma delta T cells	This study	SRA database accession code PRJNA562324
Human genome build (GRCh38/hg38)	Genome Reference Consortium	https://www.ncbi.nlm.nih.gov/grc/human

Software and algorithms

FlowJo version 10	FlowJo LLC	https://www.flowjo.com/
GraphPad Prism version 8.0.2	GraphPad Software LLC	https://www.graphpad.com
R version 3.5.1/3.5.3	R Project	https://www.r-project.org/
Salmon version 0.6.0	Patro et al. (2017)	https://salmon.readthedocs.io/en/latest/salmon.html
TraCeR	Stubington et al. (2016)	https://doi.org/10.1038/nmeth.3800
HISAT2 version 2.1.0	Daehwankim lab	https://daehwankimlab.github.io/hisat2/
SAMTools version 1.4 & version 1.9	Li et al. (2009)	http://www.htslib.org/
Cytoscape version 3.7.1	Shannon et al., (2003)	https://cytoscape.org/
Bowtie2 version 2.3.5.1	Langmead and Salzberg (2012)	http://bowtie-bio.sourceforge.net/bowtie2/index.shtml
Picard version 2.21.1	GATK	https://sourceforge.net/projects/picard/
MACS2 version 2.2.7.1	Zhang et al. (2008)	https://pypi.org/project/MACS2/
HOMER version 4.11	University of California San Diego	http://homer.ucsd.edu/homer/
IGV Genomics Viewer version 2.8.12	Broad Institute (2019)	https://software.broadinstitute.org/software/igv/
Seurat version 2.3.4 (R package)	Butler et al. (2018)	https://satijalab.org/seurat/
edgeR version 3.24.2 (R package)	Robinson et al. (2010) McCarthy et al. (2012)	https://bioconductor.org/packages/release/bioc/html/edgeR.html

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Benjamin Willcox (b.willcox@bham.ac.uk).

Materials availability

This study did not generate new unique reagents.

Data and code availability

Raw data utilised in this study has been uploaded to the SRA database, under the accession code PRJNA562324 and the project title “Epigenetic and transcriptional profiling of human gamma delta T cells”.

This paper does not report any original code.

Any additional information required to reanalyze the data reported in this paper is available from the [lead contact](#) upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Ethical approval and samples

Peripheral blood samples were obtained from healthy donors or from buffy packs. All donors provided written informed consent for sample collection and subsequent analysis; project approval for this aspect of the study was granted by the NRES Committee West Midlands ethical board (REC reference 14/WM/1254) or for buffy packs by the Australian Red Cross (ARC) Lifeblood ethics committee and Monash University Human Research Ethics Committee (Reference, 19,488 and 14,487). Samples from patients undergoing renal transplantation were obtained at the Academic Medical Centre, Amsterdam; the medical ethics committee of the Academic Medical Center, Amsterdam, approved this arm of the study and all subjects provided written informed consent in accordance with the Declaration of Helsinki. Umbilical cord blood units were obtained from the Anthony Nolan Cell Therapy Centre Nottingham (ANCTC) under generic tissue bank ethics held by ANCTC and extended to the researchers under a material transfer agreement (MTA). Paediatric healthy volunteer samples were obtained as part of the TRICICL study (Tracking the Immune changes in children with cancer) with IRAS number 233593 and REC reference 17/WM/0453; health research authority and ethics approval was obtained from South Birmingham research ethics committee. Peripheral blood samples from two subjects participating in the controlled human malaria infection (CHMI) study were also included. Heparinized venous blood was collected at baseline (before infection), and twenty days (d) after the first (CHMI1), third (CHMI3), and for one subject, fourth *P. falciparum* infection (CHMI4). Subjects were infected by bites of mosquitos carrying *P. falciparum* (strain NF54) and were treated with anti-malarial drugs (Malarone and CoArtem as a secondary treatment) based upon the detection of two unquestionable parasites by blood smear. Both subjects gave written informed consent and the study was approved by the medical ethics committee of the University of Maryland, Baltimore (ClinicalTrials.gov, NCT03014258).

METHOD DETAILS

T-cell isolation, culture, activation

PBMC were isolated from heparinised venous blood or buffy packs by using lymphoprep[®] (Stem Cell Technologies) density gradients. Resulting PBMC were frozen in liquid nitrogen and thawed to be used for subsequent experiments. Cells were sorted on an ARIA III Fusion Cell Sorter (BD Bioscience) at the University of Birmingham or FlowCore, Monash University. PBMC and purified T-cells were cultured in RPMI-1640 medium (Invitrogen) supplemented with 2 mM L-glutamine, 1% sodium pyruvate, 50 μ g/mL penicillin/streptomycin (Invitrogen) and 10% fetal calf serum (Sigma). In total, $V\delta 1^+$ T_{effector} (CD27^{lo/neg}) populations were sorted from 6 healthy donors, and $V\delta 1^+$ T_{naive} (CD27^{hi}) from 3, CD8⁺ T_{naive} from 7, and CD8⁺ T_{EMRA} populations were obtained from 9, with comparator $V\delta 2^+$ populations obtained from 2 individuals ([Davey et al., 2017](#)).

Antibodies and flow cytometry

For phenotypic analysis and cell sorting, freshly isolated, frozen PBMC or cultured cells were labelled with Zombie Aqua viability dye (Biolegend), and $V\delta 1^+$ and $V\gamma 9^+V\delta 2^+$ populations were identified with anti-CD3 (UCHT1; Biolegend), TCR $\alpha\beta$ (IP26; ThermoFisher), TCR $V\delta 1$ (REA173; Miltenyi), TCR $V\delta 2$ (123R3; Miltenyi), TCR $V\gamma 9$ (IMMU360; Beckman Coulter), CD27 (M-T271; Biolegend) and CD45RA (HI100; Biolegend) and various combinations of CXCR3 (GO25H7), CX₃CR1 (2A9-1), CD127 (A019D5), CD45RO (UCHL1), CD161 (HP-3G10), all Biolegend; or NKG2A (Z199; Beckman Coulter). Populations were gated as outlined previously ([Davey et al., 2017](#)). For intracellular staining, cells were fixed in IC Fixation buffer (eBioscience) after surface antibody staining and finally stained in Permeabilisation Buffer (eBioscience) with antibodies directed against Granzyme A (CB9), Granzyme B (GB11), Perforin (B-D48), TCF7 (7F11A19), all Biolegend; EOMES (WD1928, Invitrogen); Blimp-1 (6D3) and Hobit (Sanquin-Hobit/1), both BD Biosciences; and T-bet (eBio4B10) and PLZF (21F7), both eBioscience. Cells were acquired on a Fortessa (BD Biosciences) and data analysed using FlowJo V10.1 (TreeStar & BD Biosciences). For detection of intracellular cytokines, cells were stimulated with 10 ng/mL PMA and 1 μ g/mL ionomycin (both Sigma) for 1 h before adding 5 μ g/mL brefeldin A (ThermoFisher) and 2 μ M monensin (BD Biosciences) to the cultures for 4 h prior to harvesting. Surface-stained cells were labeled using the Fix & Perm kit (ThermoFisher) and monoclonal antibodies against IFN γ (4S.B3), TNF α (mAb11), CCL5 (VL1), IL-2 (MQ1-17H12), IL-17A (BL168), GM-CSF (BVD2-21C11), all Biolegend.

Single cell transcriptomics analysis

Single CD3⁺ TCR- $\alpha\beta$ ^{neg} $V\delta 1^+$ T-cells (CD27^{hi} or CD27^{lo/neg}) from three donors were sorted directly into the wells of 96 well PCR plates containing 2 μ L of 0.2% Triton X-100 (Sigma) with 2 U/ μ L recombinant RNase inhibitor (Takara Bio) and frozen at -80°C . cDNA was generated using the SmartScribe Reverse Transcriptase (Takara Bio Cat. 639,538), preamplified using the KAPA HiFi Hot Start Ready Mix, and sequencing libraries generated with the Nextera XT kit, following the protocol of [Picelli et al. \(2014\)](#).

Gene expression was quantified using Salmon (Patro et al., 2017), exporting transcripts per million (TPM) (version 0.6.0). Downstream analysis was completed using the *Seurat* package (v 2.3.4) (Butler et al., 2018) in R (v 3.5.3) (Team, 2000). Ensembl genes were mapped to HUGO gene symbols using the *biomaRt* package for R (Durinck et al., 2009). Upon conversion, 1,483 genes were not annotated and were discarded. Where symbols were not available, ensembl IDs were used. Genes were subsequently re-scaled to sum to 1 million and summated for those Ensembl genes which resolved to the same gene name. Three cells were deemed outliers by PCA analysis, and genes were filtered according to the *Seurat* package user guide. Data were separated into two clusters using the `FindClusters()` function under default conditions other than a resolution of 0.5. Data were displayed using PCA dimension reduction. To determine the number of significant principal components, both an Elbow plot and a JackStraw plot (100 replications) were constructed. An 'elbow' was observed at PC2, and PC1 and PC2 were deemed significant by JackStraw analysis. PC1 was the most significant principal component and was, therefore, further investigated between the clusters. Differential gene expression utilised a bimodal test within *Seurat*, an FDR cut-off of 0.05 (Bonferroni corrected), and a Log(Fold Change) threshold of 0.25. Interclone differences were calculated by a one-versus-many approach. The largest expanded clones for each donor (A, E, and K) were taken and individually compared to the others i.e. A versus E and K.

Reconstruction of $\gamma\delta$ TCR sequences from single cell RNAseq

$\gamma\delta$ TCR sequences were reconstructed from single cell transcriptomes, using TraCeR as previously described (Stubbington et al., 2016). TCR γ and TCR δ reference files were constructed from IMGT (Lefranc et al., 2009) reference sequences using the 'build' command of TraCeR. Given previous observations of long junctional regions for TCR δ (Davey et al., 2017; Hunter et al., 2018), the 'max_junc_len' parameter was increased to 100.

Bulk RNAseq analysis

Naive (CD27^{hi}) and effector (CD27^{lo/neg}) V δ 1⁺ T-cells or CD8⁺ naive (CD27^{hi} CD45RA^{hi}) and T_{EMRA} (CD27⁻ CD45RA^{hi}) cells were sorted into RNeasy (Qiagen) lysis buffer. Total RNA was isolated using the RNeasy kit (Qiagen) according to the manufacturer's instructions and RNA sequencing was performed by Genomics Birmingham (Birmingham, UK) or the Medical Genomics facility (MHTP, Clayton, Australia). FASTQ files were aligned to hg38 using HISAT2 (version 2.1.0) (Kim et al., 2015) under default conditions for paired-end alignment (average alignment of 90.90%). Reads were indexed using SAMtools (version 1.4) (Li et al., 2009) and counts were generated from the bam files with the *Rsubread* package (version 1.32.2) (Liao et al., 2013) in R (version 3.5.1) using the inbuilt annotation for the hg38 genome assembly. Batch effects were removed from the count data using the *CountClust* package for R (Dey et al., 2017; Taddy, 2012). Outliers were determined using PCA and the *arrayQualityMetrics* R package (Kauffmann et al., 2009) in accordance with outlier removal performed by Guinney et al. (Guinney et al., 2015). Downstream analyses utilised the *edgeR* package (version 3.24.2) (Robinson et al., 2010) (McCarthy et al., 2012). As suggested in the *edgeR* user guide, reads were filtered based on counts per million (CPM). Using a threshold of 6–7 reads in the sample with the smallest library, the CPM scaling factor was calculated. Genes with a CPM above 3.04 in at least two samples (smallest cell population) were kept for further analysis as suggested. This filtering step removed 15,768 lowly expressed transcripts, including 5,640 that were 0 in all 27 samples. Filtered reads were passed to the `plotMDS()` function, using all available reads for multidimensional scaling. Utilisation of *voom* transformation allowed the use of the *limma* (version 3.38.3) package for differential gene expression analysis (Law et al., 2014; Ritchie et al., 2015). Genes were adjusted using the Benjamin-Hochberg method, as is the default and were considered significant if $p < 0.05$. Geneset enrichment analysis utilised the GO and KEGG database of terms, using the camera method (*limma* package). Genesets with less than 10 or more than 300 genes were discarded. The output of geneset enrichment analysis were visualised using Cytoscape (Shannon et al., 2003) (version 3.7.1) and the *RCy3* package (version 2.2.6) (Ono et al., 2015). A similarity threshold of 0.25 was based on the Jaccard coefficient, and only genesets passing the 0.001 q value threshold were plotted. The graphic output used a force-directed layout. Heatmaps were constructed utilising the *gplots* R package (Warnes et al., 2020), using Euclidean distance and Ward linkage.

ATACseq analysis

V δ 1⁺ T-cells, CD8⁺ T-cells and V γ 9⁺V δ 2⁺ T-cells (20,000 of each population) were sorted into MACS buffer and cells were pelleted by centrifugation at 400 \times g. ATACseq libraries were generated using the Nextera DNA Library Prep Kit (Illumina Cat. FC-121-1030) in the presence of 0.01% digitonin (Promega Cat. G9441) and amplified using NEBNext High-Fidelity 2 \times PCR Master Mix (New England Labs Cat #M0541) for 9–13 cycles (Buenrostro et al., 2015). Amplified libraries were purified using Ampure beads (Beckman Coulter) and resuspended in 0.1 \times TE before quantification on TapeStation (Agilent), pooling and sequencing using the NextSeq 500/550 High Output kit v2.5 (Illumina) at Genomics Birmingham (Birmingham, UK). Paired end FASTQ files were aligned to the GRCh38 genome assembly using Bowtie2 (Langmead and Salzberg, 2012) (version 2.3.5.1), and sorted and indexed using SAMtools (version 1.9). Average number of fragments was 34,056,451, with 89.09% alignment to the reference genome. Samples had a relatively low alignment to the mitochondrial genome (4.21%) Duplicate sequences due to PCR were removed using Picard (Broad Institute, 2019) (version 2.21.1) and peaks were called using MACS2 (Zhang et al., 2008) (version 2.2.7.1) using settings of `-shift 100` and `-extsize 200`. An average of 55,236 peaks were detected. HOMER (Heinz et al., 2010) (version 4.11) was used to find consensus peaks amongst the samples, using a distance argument of 100. 21,208 consensus peaks were found of which counts were subsequently normalised to 1e7 per sample and annotated using HOMER with a `-size 400`. Raw bam files were opened in IGV Genomics Viewer (version 2.8.12), and group autoscaled for visualisation.

CD3/CD28/IL-2 stimulation assays

For assessing TCR-mediated regulation of transcription factor expression, enriched $V\delta 1^+$ and $CD8^+$ T-cells were used. Individuals with a substantial proportion of $T_{naive} V\delta 1^+$ T-cells were prioritised for these experiments. $V\delta 1^+$ T-cells were negatively enriched from PBMC through depletion of $\alpha\beta$ T-cells, B-cells, $V\delta 2^+$ T-cells, and monocytes by using a cocktail of APC-conjugated anti- $\alpha\beta$ TCR (clone IP26, Thermo Scientific), CD19 antibody (clone HIB19, TONBO biosciences), $V\delta 2$ TCR antibody (clone 123R3, Miltenyi Biotec), and CD14 antibody (clone 61D3, TONBO bioscience). $CD8^+$ T-cells were negatively enriched from PBMC through the depletion of $CD4^+$ T-cells, B-cells, $V\delta 2^+$ T-cells, $V\delta 1^+$ T-cells and monocytes by using a cocktail of APC-conjugated anti-CD4 (RPA-T4, Cy7-conjugated, BD Pharmingen), anti-CD19 antibody (clone HIB19, TONBO biosciences), anti- $V\delta 2$ TCR antibody (clone 123R3, Miltenyi Biotec), anti- $V\delta 1$ TCR antibody (clone REA173, Miltenyi Biotec), and anti-CD14 antibody (clone 61D3, TONBO bioscience). The APC-labelled cells in both settings were eliminated using EasySep Human APC Selection Kit (Stemcell Technologies). Enriched T-cells were then incubated at 37°C in the presence of plate-bound anti-CD3 antibodies (OKT-3, Biolegend) or 100 U/mL IL-2 (Peprotech) for 6 days. The expression level of relevant transcription factors in the $V\delta 1^+ T_{naive}$ ($CD27^{hi}$) and $CD8^+ T_{naive}$ subsets were measured on day 0 (unstimulated) and on day 6 of culture using flow cytometry. Data were analysed using FlowJo (version 10) software.

QUANTIFICATION AND STATISTICAL ANALYSIS

Tabulated data were analysed in Graphpad PRISM 7 (Graphpad Software Inc). Each dataset was assessed for normality using Shapiro-Wilko normality tests. Differences between groups were analyzed using one-way ANOVA with Holm-sidak's or Tukey's post-tests for normally distributed data; two-way ANOVA was used when comparing groups with independent variables. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ and **** $p < 0.0001$. Correlation was assessed with Spearman correlation, and R^2 values are reported.